References - Shodhgangashodhganga.inflibnet.ac.in/bitstream/10603/25171/... · References © Iyer...

References

182

© Iyer Sandhya Natarajan & Institute of Chemical Technology (ICT) Mumbai,

India, 2013

REFERENCES

Abla, N.; Chinn, L. W.; Nakamura, T.; Liu, L.; Huang, C. C.; Johns, S. J.; Kawamoto,

M.; Stryke, D.; Taylor, T. R.; Ferrin, T. E.; Giacomini, K. M.; Kroetz, D. L. The

human multidrug resistant protein 4 (MRP4, ABCC4): functional analysis of a

highly polymorphic gene. Journal of Pharmacology and Experimental

Therapeutics 2008, 325, 859-868.

Abraham, A.; Varatharajan, S.; Abbas, S.; Zhang, W.; Shaji, R. V.; Ahmed, R.;

Abraham, A.; George, B.; Srivastava, A.; Chandy, M.; Mathews, V.;

Balasubramanian, P. Cytidine deaminase genetic variants influence RNA

expression and cytarabine toxicity in acute myeloid leukemia.

Pharmacogenomics 2012, 13(3), 269-282.

Adema, A. D.; Radi, M.; Daft, J.; Narayanasamy, J.; Hoebe, E. K.; Alexander, L. E.;

Chu, C. K.; Peters, G. J. Troxacitabine prodrugs for pancreatic cancer.

Nucleosides, Nucloeotides & Nucleic Acids 2007, 26, 1073-1077.

Alter, P.; Herzum, M.; Soufi, M.; Schaefer, J. R.; Maisch, B. Cardiotoxicity of 5-

flurouracil. Cardiovascular and Haematological Agents in Medicinal Chemistry

2006, 4(1), 1-5.

Ameyaw, M. M.; Collie-Duguid, E. S.; Powrie, R. H.; Ofori-Adjei, D.; McLeod, H. L.

Thiopurine methyltransferase alleles in British and Ghanian populations.

Human Molecular Genetics 1999, 8, 367-370.

Amstutz, U.; Farese, S.; Aebi, S.; Largiader, C. R. Dihydropyrimidine dehydrogenase

gene variations and severe 5-flurouracil toxicity: a haplotype assessment.

Pharmacogenomics 2009, 10, 931-944.

An, H. R.; Wu, X. Q.; Wang, Z. Y.; Zhang, J. X.; Liang, Y. NAT2 and CYP2E1

polymorphisms associated with antituberculosis drug-induced hepatotoxicity in

Chinese patients. Clinical and Experimental Pharmacology and Physiology

2012, 39(6), 535-543.

Ando, H.; Kitao, T.; Miyoshi-Akiyama, T.; Kato, S.; Mori, T.; Kirikae, T.

Downregulation of katG expression is associated with isoniazid resistance in

Mycobacterium tuberculosis. Molecular Microbiology 2011, 79(6), 1615-1628.

Anitha, A.; Banerjee, M. Arylamine N-acetyltransferase 2 polymorphism in ethnic

populations of South India. International Journal of Molecular Medicine 2003,

11, 125-131.

Arenas, M.; Simpson, G.; Lewis, C. M.; Shobowale-Bakre, el-M.; Escuredo, E.;

Fairbanks, L. D.; Duley, J. A.; Ansari, A.; Sanderson, J. D.; Marinaki, A. M.

Genetic variation in the MTHFR gene influences thiopurine methyltransferase

activity. Clinical Chemistry 2005, 51, 3271-2374.

References

183


India, 2013

Arif, E.; Vibhuti, A.; Alam, P.; Deepak, D.; Singh, B.; Athar, M.; Qadar Pasha, M. A.

Association of CYP2E1 and NAT2 gene polymorphisms with chronic

obstructive pulmonary disease. Clinica Chimica Acta 2007, 382, 37-42.

Ashavaid, T. F.; Raghavan, R.; Shah, S.; Kapadia, A.; Almel, S.; Desai, D. TPMT and

DPD polymorphisms: Efficient screening method for Indian patients considering

taking thiopurine and 5-FU drugs. Disease Markers 2009, 27, 231-238.

Azuma, A.; Huang, P.; Matsuda, A.; Plunkett, W. 2’-C-cyano-2’-deoxy-1-beta-D-

arabino-pentofuranosylcytosine: a novel anticancer nuceloside analog that

causes both DNA strand breaks and G(2) arrest. Molecular Pharmacology 2001,

59(4), 725-731.

Badagnani, I.; Chan, W.; Castro, R. A.; Brett, C. M.; Huang, C. C.; Stryke, D.;

Kawamoto, M.; Johns, S. J.; Ferrin, T. E.; Carlson, E. J.; Burchard, E. G.;

Giacomini, K. M. Functional analysis of genetic variants in the human

concentrative nucleoside transporter 3 (CNT3; SLC28A3). The

Pharmacogenomics Journal 2005, 5(3), 157-165.

Bagger, Y. Z.; Jorgensen, H. L.; Heegaard, A. M.; Bayer, L.; Hansen, L.; Hassager, C.

No major effect of estrogen receptor gene polymorphisms on bone mineral

density or bone loss in postmenopusal Danish women. Bone 2000, 26(2), 111-

116.

Bakayev, V.; Mohammadi, F.; Bahadori, M.; Sheikholslami, M.; Javeri, A.; Masjedi,

M. R.; Velayati, A. A. Arylamine N-acetyltransferase 2 slow acetylator

polymorphisms in unrelated Iranian individuals. European Journal of Clinical

Pharmacology 2004, 60, 467-471.

Baker, C. H.; Banzon, J.; Bollinger, J. M.; Stubbe, J.; Samano, V.; Robins, M. J.;

Lippert, B.; Jarvi, E.; Resvick, R. 2’-Deoxy-2’-methylenecytidine and 2’-

deonxy-2’,2’-deoxycytidine 5’-diphosphates: potent mechanism-based inhibitors

of ribonucleotide reductases. Journal of Medicinal Chemistry 1991, 34, 1879-

1884.

Bakkeren, J. A.; De Abreu, R. A.; Sangers, R. C.; Gabreels, F. J.; Maas, J. M.; Reiner,

W. O. Elevated urine, blood and cerebrospinal fluid levels of uracil and thymine

in a child with dihydrothymine dehydrogenase deficiency. Clinica Chimica Acta

1984, 140, 247-256.

Banerjee, A.; Dubnau, E.; Quernard, A.; Balasubramanian, V.; Um, K. S.; Wilson, T.;

Collins, D.; de Lisle, G.; Jacobs, W. R. Jr. inhA, a gene encoding a target for

isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994, 263,

227-230.

Bardou, F.; Raynaud, C.; Ramos, C.; Laneelle, M. A.; Laneelle, G. Mechanism of

isoniazid uptake in Mycobacterium tuberculosis. Microbiology 1998, 144(9),

2539-2544.

References

184


India, 2013

Bass, J. B.; Farer, L. S.; Hopewell, P. C.; O’Brien, R.; Jacobs, R. F.; Ruben, F.;

Snider, D. E. Jr; Thornton, G. Treatment of tuberculosis and tuberculosis

infection in adults and children. American Thoracic Society and the Centers for

Disease Control and Prevention. American Journal of Respiratory and Critical

Care Medicine 1994, 149, 1359-1374.

Baturin, A. K.; Pogozheva, A. V.; Sorokina, Elu.; Makurina, O. N.; Tutel`ian, V. A.

The Trp64Arg polymorphism of beta3-adrenoreceptor study in persons with

overweight and obesity. Voprosy Pitaniia 2012, 81(2), 23-27.

Baumel-Alterzon, S.; Weber, C.; Guillen, N.; Ankri, S. Identification of

dihydropyrimidine dehydrogenase as a virulence factor essential for the survival

of Entamoeba histolytica in glucose-poor environments. Cellular Microbiology

2013, 15(1), 130-144.

Belfer, I.; Buzas, B.; Evans, C.; Hipp, H.; Pjilips, G.; Taubman, J.; Lorincz, I.;

Lipsky, R. H.; Enoch, M. A.; Max, M. B.; Goldman, D. Haplotype structure of

the beta adrenergic receptor genes in US Caucasians and African Americans.

European Journal of Human Genetics 2005, 13, 341-351.

Belt, J. A.; Marina, N. M.; Phelps, D. A.; Crawford, C. R. Nucleoside transport in

normal and neoplastic cells. Advances in Enzyme Regulation 1993, 33, 235-252.

Beutler, E. Study of glucose-6-phosphate dehydrogenase: history and molecular

biology. American Journal of Hematology 1993, 42, 53-58.

Bhatla, D.; Gerbing, R. B.; Alonzo, T. A.; Conner, H.; Ross, J. A.; Meshinchi, S.;

Zhai, X.; Zamzow, T.; Mehta, P. A.; Geiger, H.; Perentesis, J.; Davies, S. M.

Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in

children treated with acute myeloid leukaemia. British Journal of Hematology

2009, 144, 388-394.

Bhutia, Y. D.; Hung, S. W.; Patel, B.; Lovin, D.; Govindarajan, R. CNT1 expression

influences proliferation and chemosensitivity in drug-resistant pancreatic cancer

cells. Cancer Research 2011, 71(5), 1825-1835.

Blum, M.; Demierre, A.; Grant, D. M.; Heim, M.; Meyer, U. A. Molecular

mechanism of slow acetylation of drugs and carcinogens in humans.

Proceedings of the National Academy of Sciences of the United States of

America 1991, 88, 5237-5241.

Blum, M.; Grant, D. M.; McBride, W.; Heim, M.; Meyer, U. A. Human arylamine N-

acetyltransferase genes: isolation, chromosomal localization, and functional

expression. DNA and Cell Biology 1990, 9, 193-203.

Boisdron-Celle, M.; Remaud, G.; Traore, S.; Poirier, A. L.; Gamelin, L.; Morel, A.;

Gamelin, E. 5-flurouracil-related severe toxicity: a comparison of different

methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase

deficiency. Cancer Letters 2007, 249, 271-282.

References

185


India, 2013

Bokemeyer, C.; Gerl, A.; Schoffski, P.; Harstrick, A.; Niederie, N.; Beyer, J.; Casper,

J.; Schmoll, H. J.; Kanz, L. Gemcitabine in patients with relapsed or cisplatin-

refractory testicular cancer. Journal of Clinical Oncology 1999, 17, 512-516.

Boukouvala, S.; Fakis, G. Arylamine N-aceyltransferases: What we learn from genes

and genomes. Drug Metabolism Reviews 2005, 37, 511-564.

Bozic, I.; Antal, T.; Ohtsuki, H.; Carter, H.; Kim, D.; Chen, S.; Karchin, R.; Kinzler,

K. W.; Vogelstein, B.; Nowak, M. A. Accumulation of driver and passenger

mutations during tumour progression. Proceedings of the National Academy of

Sciences of the United States of America 2010, 107(43), 18545-18550.

Brockmoller, J.; Tzvetkov, M. V. Pharmacogenomics: data, concepts and tools to

improve drug discovery and drug treatment. European Journal of Clinical

Pharmacology 2008, 64, 133-157.

Brody, J. R.; Kern, S. E. History and principles of conductive media for standard

DNA electrophoresis. Analytical Biochemistry 2004, 333, 1-13.

Brown, M. A.; Haughton, M. A.; Grant, S. F.; Gunnell, A. S.; Henderson, N. K.;

Eisman, J. A. Genetic control of bone density and turnover : role of the collagen

1alpha1, estrogen receptor, and vitamin D receptor genes. Journal of Bone and

Mineral Research 2001, 16(4), 758-764.

Butcher, N. J.; Arulpragasam, A.; Minchin, R. F. Proteosomal degradation of N-

acetyltransferase 1 is prevented by activation of the active site cysteine: a

mechanism for the slow acetylator phenotype and substrate dependent down-

regulation. The Journal of Biological Chemistry 2004, 279(21), 22131-22137.

Butcher, N. J.; Boukouvala, S.; Sim, E.; Minchin, R. F. Pharmacogenetics of the N-

acetyltransferases. The Pharmacogenomics Journal 2002, 2, 30-42.

Byoung, K. Y.; Gredler, R.; Vozhilla, N.; Su, Z-Z.; Chen, D.; Forcier, T.; Shah, K.;

Saxena, U.; Hansen, U.; Fisher, P. B.; Sarkar, D. Identification of genes

conferring resistance to 5-FU. Proceedings of the Academy of Sciences of the

United States of America 2009, 106(31), 12938-12943.

Camiener, G. W.; Smith, C. G. Studies of the enzymatic deamination of cytosine

arabinoside. I. Enzyme distribution and species specificity. Biochemical

Pharmacology 1965, 14, 1405-1416.

Canellakis, E. S. Pyrimidine metabolism. I. Enzymatic pathways of uracil and

thymine degradation. Journal of Biological Chemistry 1956, 1, 315-322.

Caronia, D.; Martin, M.; Sastre, J.; de La Torre, J.; Garcia-Saenz, J. A.; Alonso, M.

R.; Moreno, L. T.; Pita, G.; Diaz-Rubio, E.; Benitez, J.; Gonzalez-Neira, A. A

polymorphism in the cytidine deaminase promoter predicts severe capecitabine

induced hand-foot syndrome. Clinical Cancer Research 2011, 17(7), 2006-

2013.

References

186


India, 2013

Carpi, F. M.; Vincenzetti, S.; Micozzi, D.; Vita, A.; Napolioni, V. PCR-based

methods for CDA K27Q and A70T genotyping: genotypes and alleles

distribution in a central Italy population. Molecular Biology Reports 2010,

37(7), 3363-3368.

Cass, C. E.; Young, J. D.; Baldwin, S. A.; Cabrita, M. A.; Graham, K. A.; Griffiths,

M.; Jennings, L. L.; Mackey, J. R.; Ng, A. M.; Ritzel, M. W.; Vickers, M. F.;

Yao, S. Y. Nucleoside transporters of mammalian cells. Pharmaceutical

Biotechnology 1999, 12, 313-352.

Celik, I.; Kars, A.; Guc, D.; Tekuzman, G.; Ruacan, S. Dihydropyrimidine

dehydrogenase enzyme deficiency: clinical and genetic assessment of

prevalence in Turkish cancer patients. Cancer Investigation 2002, 20, 333-339.

Chazal, M.; Etienne, M. C.; Rene´e, N.; Bourgeon, A.; Richelme, H.; Milano, G. A.

Link between dihydropyrimidine dehydrogenase activity in peripheral blood

mononuclear cells and liver. Clinical Cancer Research 1996, 2, 507–510.

Chen, C. L.; Liu, Q.; Pui, C. H.; Rivera, G. K.; Sandlund, J. T.; Ribeiro, R.; Evans, W.

E.; Relling, M. V. Higher frequency of Glutathione S-transferase deletions in

black children with acute lymphoblastic leukaemia. Blood 1997, 89, 1701-1707.

Chen, C.; Liu, Q.; Relling, M. V. Simultaneous characterization of glutathione S-

transferase M1 and T1 polymorphisms by polymerase chain reaction in

American whites and blacks. Pharmacogenetics 1996, 6, 187-191.

Chen, C.; Mireles, R. J.; Campbell, S. D.; Lin, J.; Mills, J. B.; Xu, J. J.; Smolarek, T.

A. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase

inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metabolism and

Disposition: The Biological Fate of Chemicals 2005, 33(4), 537-546.

Chen, Y.; Wang, X.; Yan, Z.; Wang, J.; Luo, J.; Liu, Q. Hepatic arterial infusion with

irinotecan, oxaliplatin,and floxuridine plus systematic chemotherapy as first-line

treatment of unresectable liver metastases from colorectal cancer. Onkologie

2012, 35(9), 480-484.

Chou, K. M.; Kukhanova, M.; Cheng, Y. C. A novel action of human apurinic/

apyrimidinic endonucleas: excision of L-configuration deoxyribonucleoside

analogs from the 3’ termini of DNA. The Journal of Biological Chemistry 2000,

275, 1009-1015.

Choudhary, S.; Ung, N.; Avila, P. C.; Ziv, E.; Nazario, S.; Casal, J.; Torres, A.;

Gorman, J. D.; Salari, K.; Rodriguez-Santana, J. R.; Toscano, M.; Sylvia, J. S.;

Alloto, M.; Castro, R. A.; Salazar, M.; Gomez, I.; Fagan, J. K.; Salas, J.; Clark,

S.; Lilly, C.; Matallana, H.; Selman, M.; Chapela, R.; Sheppard, D.; Weiss, S.

T.; Ford, J. G.; Boushey, H. A.; Drazen, J. M.; Rodriguez-Cintron, W.;

Silverman, E. K.; Burchard, E. Z. Pharmacogenetic differences in response to

References

187


India, 2013

albuterol between Puerto Ricans and Mexicans with asthma. American Journal

of Respiratory and Critical Care Medicine 2005, 171, 563-570.

Chrambach, A.; Rodbard, D. Ployacrylamide gel elecrtophoresis. Science 1971, 172,

440-451.

Chu, E. Ode to 5-flurouracil. Clinical Colorectal Cancer 2007, 6(9), 609.

Ciccolini, J.; Evrard, A.; M’Batchi, L.; Pourrov, B.; Mercier, C.; Iliadis, A, Lacarelle,

B, Verschuur, A.; Ouafik, L.; Andre`, N. CDA deficiency as a possible culprit

for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy:

pharmacogenetic investigations. Pharmacogenomics 2012, 13(4), 393-397.

Ciccolini, J.; Mercier, C.; Dahan, L.; Andre, N. Integrating pharmacogenetics into

gemcitabine dosing –time for a change? Clinical Oncology 2011, 8, 439-444.

Cichon, S.; Nothen, M. M.; Rietschel, M.; Propping, P. Pharmacogenetics of

schizophrenia. American Journal of Medical Genetics 2000, 97, 98-106.

Coe, I. R.; Griffiths, M.; Young, J. D.; Baldwin, S. A.; Cass, C. E. Assignment of the

human equilibrative nucleoside transporter (hENT1) to 6p21.1-p21.2. Genomics

1997, 45, 459-460.

Coleman, G.; Miller, A. Electrodialysis of sugar borates. The proceeding of the Iowa

academy of sciences 1942, 49, 257-261.

Collie-Duguid, E. S.; Etienne, M. C.; Milano, G. ; McLeod, H. L. Known variant

DPYD alleles do not explain DPD deficiency in cancer patients.

Pharmacogenetics 2000, 10, 217-223.

Collie-Duguid, E. S.; Prtichard, S. C.; Powrie, R. H.; Sludden, J.; Collier, D. A.; Li,

T.; Mcleod, H. L. The frequency and distribution of thiopurine

methyltransferase alleles in Caucasian and Asian populations.


Costanzi, S.; Vilar, S.; Micozzi, D.; Carpi, F. M.; Ferino, G.; Vita, A.; Vincenzetti, S.

Delineation of the molecular mechanisms of nucleoside recognition by cytidine

deaminase through virtual screening. ChemMedChem 2011, 6(8), 1452-1458.

Cubero, D. I.; Cruz, F. M.; Santi, P.; Silva, I. D.; Del Giglio, A. Tegafur-uracil is a

safe alternative for the treatment of colorectal cancer in patients with partial

dihydropyrimidine dehydrogenase deficiency: a proof of principle. Therapeutic

Advances in Medical Oncology 2012, 4(4), 167-172.

Cui, X.; Lu, X.; Hiura, M.; Omori, H.; Miyazaki, W.; Katoh, T. Association of

genotypes of carcinogen-metabolizing enzymes and smoking status with

bladder cancer in a Japanese population. Environmental Health and Preventive

Medicine 2012 [Article in press].

References

188


India, 2013

Dally, H.; Edler, L.; Jager, B.; Schmezer, P.; Spiegelhalder, B.; Dienemann, H.;

Drings, P.; Schulz, V.; Kayser, K.; Bartsch, H.; Risch, A. The CYP3A4*1B

allele increases risk for small cell lung cancer: effect of gender and smoking

dose. Pharmacogenetics 2003, 13, 607-618.

Dahan, L.; Ciccolini, J.; Mercier, M.; Duluc, P.; Ries, P.; Norguet, E.; Oculi, C.;

Evrard, A.; Ouafik, L.; Seitz, J. F. Treatment failure upon gemcitabine intake: Is

cytidine deaminase extensively the ideal culprit? Journal of Clinical Oncology

2010, 28, e14558.

Dahan, L.; Ciccolini, J.; Evrard, A.; Mbatchi, L.; Tibbitts, J.; Ries, P.; Norguet, E.;

Mercier, C.; Iliadis, A.; Ouafik, L.; Lacarelle, B.; Seitz, J. F. Sudden death

related toxicity in a patient on capecitabine and irinotecan plus bevacizumab

intake: pharmacogenetic implications. Journal of Clinical Oncology 2012,

30(4), e41-e44.

Damaraju, V. L.; Damaraju, S.; Young, J. D.; Baldwin, S. A.; Mackey, J.; Sawyer, M.

B.; Cass, C. E. Nucleoside anticancer drugs: the role of nucleoside transporters

in resistance to cancer chemotherapy. Oncogene 2003, 22, 7534-7536.

Dang, M. T.; Hambleton, J.; Kayser, S. R. The influence of ethnicity on warfarin

dosage requirement. The Annals of Pharmacotherapy 2005, 39, 1008-1012.

Danna, K.; Nathans, D. Specific clevage of simian virus 40 DNA by restriction

endonuclease of Hemophilus influenzae. The proceesings of the National

Academy of Sciences of the United States of America 1971, 68, 2913-2917.

De’epiro, S.; Salvi, M.; Mattozzi, C.; Giancristoforo, S.; Campoli, M.; Zanniello, R.;

Luci, C.; Macaluso, L.; Giovannoni, S.; Iacovelli, R.; Calvieri, S.; Richetta, A.

G. Gemcitabine induced extensive skin necrosis. Case Reports in Medicine

2012, 2012: 831616.

De Koning, H. P.; Bridges, D. J.; Burchmore, R. J. Purine and pyrimidine transport in

pathogenic protozoa: from biology to therapy. FEMS Microbiology Review

2005, 29(5), 987-1020.

Delomenie, C.; Fouix, S.; Longeumaux, S.; Brahimi, N.; Bizet, C.; Picard, B.;

Denamur, E.; Dupert, J. M. Identification and functional characterization of

arylamine N-acetyltransferases in eubacteria: Evidence for highly selective

acetylation of 5-aminosalicylic acid. Journal of Bacteriology 2001, 183, 3417-

3427.

Derakhshandeh, K.; Fathi, S. Role of chitosan nanoparticles in the oral absorption of

gemcitabine. International Journal of Pharmaceutics 2012, 437, 172-177.

Dhanya, P.; Bindu Latha, N.; Jayakumar, K. L.; Ramani, P. Comparitive study of the

toxicity of 5-fluorouracil-adriamycin-cyclophosphamide versus adriamycin-

cyclophosphamide followed by paclitaxel in carcinoma breast. Indian Journal of

Cancer 2011, 48, 68-73.

References

189


India, 2013

Diasio, R. B.; Beavers, T. L.; Carpenter, J. T. Familial deficiency of

Dihydropyrimidine dehydrogenase. Biochemical basis for familial

pyrimidinemia and severe 5-fluorouracil-induced toxicity. The Journal of

Clinical Investigation 1988, 81, 47–51.

Diasio, R. B.; Harris, B. E. Clinical pharmacology of 5-flurouracil. Clinical

Pharmacokinetics 1989, 16, 215-237.

Dilmec, F.; Varisli, L.; Ozgonul, A.; Cen, O.; Uzunkoy, A. Analysis of DPYD gene

using bioinformatics tools. Turkiye Klinikleri Journal of Medical Sciences 2007,

27(6), 829-837.

Dobritzsch, D.; Schneider, G.; Schnackerz, K. D.; Lindqvist, Y. Crystal structure of

dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics

of the anti-cancer drug 5-flurouracil. The EMBO Journal 2001, 20, 650-660.

Doll, M. A.; Fretland, A. J.; Deitz, A. C.; Hein, D. W. Determination of human NAT2

acetylator genotype by restriction fragment-length polymorphism and allele-

specific amplification. Analytical Biochemistry 1995, 231(2), 413-420.

Dong, X. W.; Zheng, Q.; Zhu, M. M.; Tong, J. L.; Ran, Z. H. Thiopurine S-

methyltransferase polymorphisms and thiopurine toxicity in treatment of

inflammatory bowel disease. World Journal of Gastroenterology 2010, 16,

3187-3195.

Du, H.; Cehn, X.; Fang, Y.; Yan, O. ; Xu, H. ; Li, L. ; Li, W. ; Huang, W. Slow N-

acetyltransferase 2 genotype contributes to anti-tuberculosis induced

hepatotoxicity: a meta-analysis. Molecular Biology Reports 2013 [Article in

press].

Duga, S.; Solda, G.; Asselta, R.; Bonati, M. T.; Dalpra, L.; Malcovati, M.; Tenchini,

M. L. Characterization of the genomic structure of the human neuronal nicotinic

acetylcholine receptor CHRNA5/A3/A4 gene cluster and identification of novel

intragenic polymorphisms. Journal of Human Genetics 2001, 46, 640-648.

Dupert, J. M.; Grant, D. M. Site-directed mutagenesis of recombinant human

arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct

involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2.

The Journal of Biological Chemistry 1992, 267, 7381-7385.

Eichelbaum, M.; Fromm, M. F.; Schwab, M. Clinical aspects of the MDR1 (ABCB1)

gene polymorphism. Therapeutic Drug Monitoring 2004, 26, 180.

Endrizzi, B.; Ahmed, R. L.; Ray, T.; Dudek, A.; Lee, P. Capecitabine to reduce

nonmelanoma skin carcinoma burden in solid organ transplant recipients.

Dermatologic Surgery 2013 [Article in press].

Engel, K.; Wang, J. Interaction of organic cations with a newly identified plasma

membrane monoamine transporter (PMAT). Molecular Pharmacology 2005,

68, 1397-1407.

References

190


India, 2013

Etienne, M. C.; Chatelut, E.; Pivot, X.; Lavit, M.; Pujol, A.; Canal, P.; Milano, G. Co-

variables influencing 5-fluorouracil clearance during continuous venous

infusion. A NONMEM analysis. European Journal of Cancer 1998, 34, 92–97.

Etienne, M. C.; Che´radame, S.; Fischel, J. L.; Formento, P.; Dassonville, O.; Renee,

N.; Schneider, M.; Thyss, A.; Demard, F.; Milano, G. Response to fluorouracil

therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase

activity. Journal of Clinical Oncology 1995, 13, 1663–1670.

Etienne, M. C.; Lagrange, J. L.; Dassonville, O.; Fleming, R.; Thyss, A.; Renee, N.;

Schneider, M.; Demard, F.; Milano, G. Population study of Dihydropyrimidine

dehydrogenase in cancer-patients. Journal of Clinical Oncology 1994, 12, 2248-

2253.

Evans, D. A. N-acetyltransferase. In Pharmacogenetics of drug metabolism; Kalow,

W., Ed.; New York, Pergamon Press, 1992; pp 95-178.

Evans, D. A. N-acetyltransferase. Pharmacology & Therapeutics Journal 1989, 42,

157-234.

Evans, W. E.; Relling, M. V. Pharmacogenomics: translating functional genomics into

rational therapeutics. Science 1999, 286, 487-491.

Fertrin, K. Y.; Goncalves, M. S.; Saad, S. T.; Costa, F. F. Frequencies of UDP-

glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among

distinct ethnic groups from Brazil. American Journal of Medical Genetics 2002,

108, 117-119.

Fidlerova, J.; Kleiblova, P.; Kormunda, S.; Novotny, J.; Kleibl, Z. Contribution of the β-ureidopropionase (UPB1) gene alterations to the development of

fluoropyrimidine-related toxicity. Pharmacological Reports 2012, 64(5), 1234-

1242.

Fukao, M.; Ishida, K.; Sakamoto, T.; Taguchi, M.; Matsukura, H.; Miyawaki, T.;

Hashimoto, Y. Effect of genetic polymorphisms of SLC28A1, ABCG2, and

ABCC4 on bioavailability of mizoribine in healthy Japanese males. Drug

Metabolism and Pharmacokinetics 2011, 26(5), 538-543.

Fukunaga, A. K.; Marsh, S.; Murry, D. J.; Hurley, T. D.; McLeod, H. L. Identification

and analysis of single-nucleotide polymorphisms in the gemcitabine

pharmacologic pathway. The Pharmacogenomics Journal 2004, 4, 307-314.

Galvan, C. A.; Elbarcha, O. C.; Fernandez, E. J.; Beltramo, D. M.; Soria, N. W.

Genetic profiling of GSTP1, DPYD, FCGR2A, FCGR3A and CCND1 genes in

an Argentinian population. Clinical Biochemistry 2011, 44(13), 1058-106.

Gamelin, E.; Boisdron-Celle, M. Dose monitoring of 5-fluorouracil in patients with

colorectal or head and neck cancer- status of the art. Critical Reviews in

Oncology/ Hematology Journal 1999, 30, 71–79.

References

191


India, 2013

Gamelin, E.; Boisdron-Celle, M.; Guerin-Meyer, V.; Delva, R.; Lortholary, A.;

Genevieve, F.; Larra, F.; Ifrah, N.; Robert, J. Correlation between uracil and

dihydrouracil plasma ratio, flurouracil (5-FU) pharmacokinetic parameters, and

tolerance in patients with advanced colorectal cancer: a potential interest for

predicting 5-FU toxicity and determining optimal 5-FU dosage. Journal of

Clinical Oncology 1999, 17, 1105-1110.

Gao, L-B.; Zhou, B.; Zhang, L.; Wei, Y-S.; Wang, Y-Y.; Liang, W-B.; Lv, M-L.; Pan,

X-M.; Chen, Y-C.; Rao, L. R497K polymorphism in epidermal growth factor

receptor gene is associated with the risk of acute coronary syndrome. BMC

Medical Genetics 2008, 9, 74.

Garrod, A. E. The incidence of alkaptonuria: a study in chemical individuality. Lancet

1902, 2, 1616-1620.

Ge, L.; Wang, H. J.; Yin, D.; Lei, C.; Zhu, J. F.; Cai, X. H.; Zhang, G. Q.

Effectiveness of 5-flurouracil based neoadjuvant chemotherapy in locally-

advanced gastric/gastroesophageal cancer: A meta-analysis. World Journal of

Gastroenterology 2012, 18(48), 7384-7393.

Gennari, L.; Becherini, L.; Masi, L. ; Mansani, R. ; Gonnelli, S. ; Cepollaro, C. ;

Martini, S. ; Montagnani, A. ; Lentini, G. ; Becorpi, A. M. ; Brandi, M. L.

Vitamin D and estrogen receptor allelic variants in Italian postmenopausal

women : evidence of multiple gene contribution to bone mineral density. The

Journal of Clinical Endocrinology and Metabolism 1998, 83(3), 939-944.

Gilbert, J. A.; Salavaggione, O. E.; Ji, Y.; Pelleymounter, L. L.; Eckloff, B. W.;

Wieben, E. D.; Ames, M. M.; Weinshilboum, R. M. Gemcitabine

pharmacogenomics : cytidine deaminase and deoxycytidylate deaminase gene

resequencing and functional genomics. Clinical Cancer Research 2006, 12,

1794-1803.

Giovannetti, E.; Laan, A. C.; Vasile, E.; Tibaldi, C.; Nannizzi, S.; Ricciardi, S.;

Falcone, A.; Danesi, R.; Peters, G. J. Correlation between cytidine deaminase

genotype and gemcitabine deamination in blood samples. Nucleosides,

Nucleotides, Nucleic acids 2008, 27, 720-725.

Giovannetti, E.; Tacca, M. D.; Mey, V.; Funel, N.; Nannizzi, S.; Ricci, S.; Orlandini,

C, Boggi, U.; Campani, D.; Del Chiaro, M.; Iannopollo, M.; Bevilacqua, G.;

Mosca, F.; Danesi, R. Transcription analysis of human equilibrative nucleoside

transporter-1 predicts survival in pancreas cancer patients treated with

gemcitabine. Cancer Research 2006, 66(7), 3928-3935.

Goldstein, D. B.; Tate, S. K.; Sisodiya, S. M. Pharmacogenetics goes genomic. Nature

Reviews Genetics 2003, 4, 937-947.

Gonzalez, F. J.; Skoda, R. C.; Kimura, S.; Umeno, M.; Zanger, U. M.; Nerbert, D. W.;

Gelboin, H. V.; Hardwick, J. P.; Meyer, U. A. Characterization of the common

References

192


India, 2013

genetic defect in humans deficient in debrisoquine metabolism. Nature 1988,

331, 442-446.

Gonzalez, F. J.; Skoda, R. C.; Kimura, S.; Umeno, M.; Zanger, U. M.; Nerbert, D. W.;

Gelboin, H. V.; Hardwick, J. P.; Meyer, U. A. Characterization of the common

genetic defect in humans deficient in debrisoquine metabolism. Nature 1988,

331, 442-446.

Goodman & Gillman’s The Pharmacological basis of Therapeutics, 7th

ed.; Rall,

T.W.; Murad, F., Ed.; Macmillan publishing company, New York, 1985; pp

1247-1251.

Grant, D. M.; Blum, M.; Beer, M.; Meyer, U. A. Monomorphic and polymorphic

human arylamine N-acetyltransferases: a comparison of liver isozymes and

expressed products of two genes. Molecular Pharmacology 1991, 39, 184-191.

Gray, J. H.; Mangravite, L. M.; Owen, R. P.; Urban, T. J.; Chan, W.; Carlson, E. J.;

Huang, C. C.; Kawamoto, M.; Johns, S. J.; Stryke, D.; Ferrin, T. E.; Giacomini,

K. M. Functional and genetic diversity in the concentrative nucleoside

transporter, CNT1, in human populations. Molecular Pharmacology 2004, 65,

512-519.

Green, M. R. Gemcitabine safety overview. Seminars in Oncology 1996, 23(10), S32-

S35.

Green, S. R.; Choudhary, A. K.; Fleming, I. N. Combination of sapacitabine and

HDAC inhibitors stimulates cell death in AML and other tumour types. British

Journal of Cancer 2010, 103(9), 1391-1399.

Green, S. A.; Cole, G.; Jacinto, M.; Innis, M.; Ligget, S. B. A polymorphism of the

beta-2-adrenergic receptor within the fourth transmembrane domains alters

ligand binding and functional properties of the receptor. The Journal of

Biological Chemistry 1993, 268, 23116-23121.

Green, S. A.; Turki, J.; Innis, M.; Liggett, S. B. Amino-terminal polymorphisms of

the human beta-2-adrenergic receptor impart distinct agonist promoted

regulatory properties. Biochemistry 1994, 33, 9414-9419.

Green, S.; Walter, P.; Kumar, V.; Krust, A.; Bornert, J. M.; Argos, P.; Chambon, P.

Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-

A. Nature 1986, 320, 134-139.

Grem, J. L.; Yee, L. K.; Venzon, D. J.; Takimoto, C. H.; Allegra, C. J. Inter- and

intraindividual variation in dihydropyrimidine dehydrogenase activity in

peripheral blood mononuclear cells. Cancer Chemotherapy and Pharmacology

1997, 40, 117–125.

Griffith, D. A.; Jarvis, S. M. Nucleoside and nucelobase transport system of

mammalian cells. Biochimica et Biophysica Acta 1996, 1286, 153-181.

References

193


India, 2013

Griffiths, M.; Beaumont, N.; Yao, S. Y.; Sundaram, M.; Boumah, C. E.; Davies, A.;

Kwong, F. Y.; Coe, I.; Cass, C. E.; Young, J. D.; Baldwin, S. A. Cloning of a

human nucleoside transporter implicated in the cellular uptake of adenosine and

chemotherapeutic drugs. Nature Medicine 1997, 3, 89-93.

Griffiths, M.; Yao, S. Y.; Abidi, F.; Phillips, S. E.; Cass, C. E.; Young, J. D.;

Baldwin, S. A. Molecular cloning and characterization of a

nitrobenzylthioinosine-sensitive (ei) equilibrative transporter from human

placenta. Biochemical Journal 1997, 328, 739-743.

Gross, E.; Busse, B.; Riemenschneider, M.; Neubauer, S.; Seck, K.; Klein, H. G.;

Kiechle, M.; Lordick, F.; Meindl, A. Strong association of a common

dihydropyrimidine dehydrogenase gene polymorphism with fluropyrimidine-

related toxicity in cancer patients. PLoS ONE 2008, 3, e4003.

Gross, E.; Ullrich, T.; Seck, K.; Mueller, V.; de Wit, M.; von Schilling, C.; Meindl,

A.; Schmitt, M.; Keichle, M. Detailed analysis of five mutations in

dihydropyrimidine dehydrogenase detected in cancer patients with 5-flurouracil-

related side effects. Human Mutation 2003, 22, 498.

Grove, K. L.; Guo, X.; Liu, S. H.; Gao, Z.; Chu, C. K.; Cheng, Y. C. Anticancer

activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the

unnatural L configuration. Cancer Research 1995, 55, 3008-3011.

Gupta, H. V.; Amarapurkar, D. N.; Singh, M.; Sasi, P.; Joshi, J. M.; Baijlal, R.;

Ramegowda, P. H.; Amarapurkar, A. D.; Joshi, K.; Wangikar, P. P. Association

of N-acetyltransferase 2 and cytochrome P450 2E1 gene poilymorphisms with

antituberculosis drug-induces hepatotoxicity in Western India. Journal of

Gastroenterology and Hepatology 2013, 28(8), 1368-1374.

Hamdy, S. I.; Hiratsuka, M.; Narahara, K.; Endo, N.; El-Enany, M.; Moursi, N.;

Ahmed, M. S.; Mizugaki, M. Genotype and allele frequencies of TPMT, NAT2,

GST, SULT1A1 and MDE-1 in the Egyptian population. British Journal of

Clinical Pharmacology 2003, 55, 560–569.

Hartl, D. L.; Clark, A. G. Principles of Population genetics, 4th

ed.; 1997, Sinauer

Asscoiates Inc Publishers, Massachusetts.

Heggie, G. D.; Sommadossi, J. P.; Cross, D. S.; Huster, W. J.; Diasio, R. B. Clinical

pharmacokinetics of 5-flurouracil and its metabolites in plasma, urine and bile.

Cancer Research 1987, 47, 2203-2206.

Hein, D. W.; Doll, M. A.; Fretland, A. J.; Leff, M. A.; Webb, S. J.; Xiao, G. H.;

Devanboyina, U. S.; Nangju, N. A.; Feng, Y. Molecular genetics and

epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer

Epidemiology, Biomarkers & Prevention 2000a, 9, 29-42.

Hein, D. W.; Doll, M. A.; Rustan, T. D.; Gray, K.; Feng, Y.; Ferguson, R. J.; Grant,

D. M. Metabolic activation and deactivation of arylamine carcinogens by

References

194


India, 2013

recombinant human NAT1 and polymorphic NAT2 acetyltransferases.

Carcinogenesis 1993, 14, 1633-1638.

Hein, D. W.; Grant, D. M.; Sim, E. Update on consensus arylamine N-

acetyltransferase gene nomenclature. Pharmacogenetics 2000b, 10, 291-292.

Heinemann, V.; Xu, Y. Z.; Chubb, S.; Sen, A.; Hertel, L. W.; Grindey, G. B.;

Plunkett, W. Cellular elimination of 2’,2’-diflurodeonxycytidine 5’-

triphosphate: a mechanism of self-potentiation. Cancer Research 1992, 52, 533-

539.

Herrington, D. M. Role of estrogen receptor-alpha in pharmacogenetics of estrogen

action. Current Opinion in Lipidology 2003, 14, 145-150.

Heym, B.; Zhang, Y.; Poulet, S.; Young, D.; Cole, S. T. Characterisation of the katG

gene encoding catalase-peroxidase required for the isoniazid susceptibility of the

Mycobacterium tuberculosis. Journal of Bacteriology 1993, 175, 4255-4259.

Hickman, D.; Risch, A.; Buckle, V.; Spurr, N. K.; Jeremiah, S. J.; McCarthy, A.; Sim,

E. Chromosomal localization of human genes for arylamine N-acetyltrasferase.

Biochemical Journal 1994, 297, 441-445.

Hiratochi, M.; Tatani, K.; Shimizu, K.; Kuramochi, Y.; Kikuchi, N.; Kamada, N.;

Itoh, F.; Isaji, M. Hypouricemic effects of novel concentrative nucleoside

transporter 2 inhibitors through suppressing intestinal absorption of purine

nucleosides. European Journal of Pharmacology 2012, 690, 183-191.

Hiratsuka, M.; Kishikawa, Y.; Takekuma, Y.; Matsuura, M.; Narahara, K.; Inoue, T.;

Hamdy, S. I.; Endo, N.; Goto, J.; Mizugaki, M. Genotyping of the N-

acetyltransferase2 polymorphism in the prediction of adverse drug reactions to

isoniazid in Japanese patients. Drug Metabolism and Pharmacokinetics 2002,

17, 357-362.

Hiratsuka, M.; Sasaki, T.; Mizugaki, M. Genetic testing for pharmacogenetics and its

clinical application in drug therapy. Clinica Chimica Acta 2006, 363, 177-186.

Hirota, T.; Date, Y.; Nishibatake, Y.; Takane, H.; Fukuoka, Y.; Taniguchi, Y.;

Burioka, N.; Shimizu, E.; Nakamura, H.; Otsubo, K.; Ieiri, I. Dihydropyrimidine

dehydrogenase (DPD) expression is negatively regulated by certain microRNAs

in human lung tissues. Lung cancer 2012, 77(1), 16-23.

Ho, D. H. Distribution of kinase and deaminase of 1-betaD-arabinofuranosylcytosine

in tissues of man and mouse. Cancer Research 1973, 33, 2816-1820.

Ho, W. F.; Koo, S. H.; Yee, J. Y.; Lee, J. D. Genetic variations of the ABCC2 gene in

the Chinese, Malay, and Indian populations of Singapore. Drug Metabolism and

Pharmacokinetics 2008, 23, 385-391.

References

195


India, 2013

Hon, Y. Y.; Fessing, M. Y.; Pui, C. H.; Relling, M. V.; Krynetski, E. Y.; Evans, W. E.

Polymorphism of the thiopurine S-methyltransferase gene in African-

Americans. Human Molecular Genetics 1999, 8, 371-376.

Hormozian, F.; Schmitt, J. G.; Sagulenko, E.; Schwab, M.; Savelyeva, L. FRA1E

common fragile site breaks map within a 370kilobase pair region and disrupt the

dihydropyrimidine dehydrogenase gene (DPYD). Cancer Letters 2007, 246, 82-

91.

Hsiao, H. H.; Yang, M. Y.; Chang, L. G.; Liu, Y. C.; Liu, T. C.; Chang, C. S.; Chen,

T. P.; Lin, S. F. Dihydropyrimidine dehydrogenase pharmacogenetics in the

Taiwanese population. Cancer Chemotherapy and Pharmacology 2004, 53, 445-

451.

Huang, J. S.; Yen, C. L.; You, Y. T.; Wang, C. H.; Lan, Y. J.; Lai, C. H.; Chueh, T.

C.; Liaw, C. C. Decreasing dosage of irinotecan, 5-flurouracil (5-FU) and

leucovorin (LV) in the treatment of advanced and/or metastatic colorectal

cancer: a phase II study. Chang Gung Medical Journal 2006, 29(3), 297-305.

Huang, P.; Robertson, L. E.; Wright, S.; Plunkett, W. High molecular weight DNA

fragmentation: a critical event in nucleoside analogue-induced apoptosis in

leukemia cells. Clinical Cancer Research 1995, 1(9), 1005-1013.

Iakoubova, O. A.; Sabatine, M. S.; Rowland, C. M.; Tong, C. H.; Catanese, J. J.;

Ranade, K.; Simonsen, K. L.; Kirchgessner, T. G.; Cannon, C. P.; Devlin, J. J.;

Braunwald, E. Polymorphism in KIF6 gene and benefit from statins after acute

coronary syndromes: results from the PROVE IT- TIMI 22 study. Journal of the

American College of Cardiology 2008b, 51, 449-455.

Iakoubova, O. A.; Tong, C. H.; Rowland, C. M.; Kirchgessner, T. G.; Young, B. A.;

Arellano, A. R.; Shiffman, D.; Sabatine, M. S.; Campos, H.; Packard, C. J.;

Pfeffer, M. A.; White, T. J.; Braunwald, E.; Shepherd, J.; Devlin, J. J.; Sacks, F.

M. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with

myocardial infarction and coronary heart disease in two prospective trials: the

CARE and WOSCOPS trials. Journal of the American College of Cardiology

2008a, 51, 435-443.

Ikeguchi, M.; Makino, M.; Kaibara, N. Thymidine phosphorylase and

dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients

prognosis. Langenbeck’s Archive of Surgery 2002, 387, 240–245.

Ingelman-Sundberg, M.; Oscarson, M.; McLellan, R. A. Polymorphic human

cytochrome P450 enzymes: an opportunity for individualized drug treatment.

Trends in Pharmacological Sciences 1999, 20, 342-349.

Issa, A. M. Personalized medicine and the practise of medicine in the 21st century.

McGill Journal of Medicine 2007, 10, 53-57.

References

196


India, 2013

Ito, S., Ieiri, I.; Tanabe, M.; Suzuki, A.; Higuchi, S.; Otsubo, K. Polymorphism of the

ABC transporter genes MDR1, MRP1 and MRP2/cMOAT in healthy Japanese

subjects. Pharmacogenetics 2001, 11, 175-184.

Jain, M.; Kumar, S.; Lal, P.; Tiwari, A.; Ghoshal, U. C.; Mittal, B. Association of

genetic polymorphisms of N-acetyltransferase 2 and susceptibility to esophageal

cancer in North Indian population. Cancer Investigation 2007, 25, 340-346.

Johnson, M. R.; Wang, K.; Diasio, R. B. Profound dihydropyrimidine dehydrogenase

deficiency resulting from a novel compound heterozygote genotype. Clinical

Cancer Research 2002, 8, 768-774.

Johnston, S. J.; Ridge, S. A.; Cassidy, J.; McLeod, H. L. Regulation of

dihydropyrimidine dehydrogenase in colorectal cancer. Clinical Cancer

Research 1999, 5, 2566–2570.

Jones, S.; Zhang, X.; Parsons, D. W.; Ho Lin, J. C.; Leary, R. J.; Angenendt, P.;

Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; Hong, SM.; Fu, B.; Lin,

MT.; Calhoun, E. S.; Kamiyama, M.; Walter, K.; Nikolskaya, T.; Nikolsky, Y.;

Hartigan, J.; Smith, D. R.; Hidalgo, M.; Leach, S. D.; Klein, A. P.; Jaffee, E. M.;

Goggins, M.; Maitra, A.; Lacobuzio-Donahue, C.; Eshleman, J. R.; Kern, S. E.;

Hruban, R. H.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.;

Velculescu, V. E.; Kinzler, K. W. Core signalling pathways in human pancreatic

cancers revealed by global genomic analyses. Science 2008, 321, 1801-1806.

Kadlubar, F. F.; Berkowitz, G. S.; Delongchamp, R. R.; Wang, C.; Green, B. L.;

Tang, G.; Lamba, J.; Schuetz, E.; Wolff, M. S. The CYP3A4*1B variant is

related to onset of puberty, a known risk factor for the development of breast

cancer. Cancer Epidemiology, Biomarkers & Prevention 2003, 12, 327-331.

Kahramanogullari, O.; Fantaccini, G.; Lecca, P.; Morpurgo, D.; Priami, C.

Algorithmic modeling quantifies the complementary contribution of metabolic

inhibitions to gemcitabine efficacy. PloS ONE 2012, 7(12), e50176.

Kaiser, R.; Taylor, K. E.; Deng, Y.; Zhao, J.; Li, Y.; Nititham, J.; Chang, M.;

Catanese, J.; Begovich, A. B.; Brown, E. E.; Edberg, J. C.; McGwin, G.;

Alarc`on, G. S.; Ramsey-Goldman, R.; Reveille, J. D.; Vila, L. M.; Petri, M.;

Kimberly, R. P.; Feng, X.; Sun, L.; Shen, N.; Li, W.; Lu, J. X.; Wakeland, E.

K.; Li, Q. Z.; Yang, W.; Lau, Y. L.; Liu, F. L.; Chang, D. M.; Yu, C. Y.; Song,

Y. W.; Hwee Siew Howe and the Tan Tock Seng hospital Systemic Lupus

Erythematosus study group; Tsao, B P.; Criswell, L. A. Brief report: Single-

nucleotide polymorphisms in VKORC1 are risk factors for systemic lupus

erythematosus in Asians. Arthritis and Rheumatism 2013, 65, 211-215.

Kalow, W. Pharmacogenetics and anaesthesia. Anaesthesiology 1964, 25, 377-387.

Kalow, W.; Tang, B. K.; Endrenyi, L. Hypothesis: comparisons of inter- and intra-

individual variations can substitute for twin studies in drug research.


References

197


India, 2013

Kaniwa, N.; Kurose, K.; Tinno, H.; Tanaka-Kagawa, T.; Saito, Y.; Saeki, M.;

Sawada, J.; Tohkin, M.; Hasegawa, R. Racial variability in haplotype

frequencies of UGT1A1 and glucuronidation activity of a single nucleotide

polymorphism 686C>T (P229L) found in African-American. Drug Metabolism

and Disposition: the Biological Fate of Chemicals 2005, 33, 458-465.

Kantarjian, H.; Garcia-Manero, G.; O’Brien, S, Faderi, S.; Ravandi, F.; Westwood,

R.; Green, S. R.; Chiao, J. H.; Boone, P. A.; Cortes, J.; Plunkett, W. Phase I

clinical and pharmacokinetic study of oral sapacitabine in patients with acute

leukemia and myelodysplastic syndrome. Journal of Clinical Oncology 2010,

28(2), 285-291.

Kaplan, M. A.; Isikdogen, A, Koca, D.; Kucukoner, M.; Gumusay, O.; Yildiz, R.;

Dayan, A.; Demir, L.; Geredeli, C.; Kocer, M.; Arslan, U. Y.; Inal, A.; Akman,

T.; Coskun, U.; Sener, N.; Inanc, M.; Elkiran, E. T,; Ozdemir, N. Y.; Durnali,

A. G.; Suner, A.; Alici, S.; Tarhan, M. O.; Bourban, C.; Oksuzoglu, B.; Urakci,

Z. Clinical outcomes in patients who received lapatinib plus capecitabine

combination therapy for HER2-positive breast cancer with brain metastases and

a comparison of survival with those who received trastuzumab-based therapy: a

study by the Anatolian Society of Medical Oncology. Breast Cancer 2013

[Article in press].

Kelly, C. L.; Rouse, D. A.; Morris, S. L. Analysis of ahpC gene mutations in

isoniazid-resistant clinical isolates of Mycobacterium tuberculosis.

Antimicrobial Agents and chemotherapy 1997, 41, 2057-2058.

Kertai, M. D.; Fontes, M.; Podgoreanu, M. V. Pharmacogenomics of beta-blockers

and statins: Possible implications for perioperative cardiac complications.

Journal of Cardiothoracic and Vascular Anesthesia 2012, 26, 1101-1114.

Keshava, C.; McCanlies, E. C.; Weston, A. CYP3A4 polymorphisms- Potential risk

factors for breast and prostrate cancer: A HuGE review. American Journal of

Epidemiology 2004, 160(9), 825-841.

Kessel, D. Cell surface alterations associated with exposure of leukemia L1210 cells

to flurouracil. Cancer Research 1980, 40, 322-324.

Keskitalo, J. E.; Kurkinen, K. J.; Neuvoneni, P. J.; Niemi, M. ABCB1 haplotypes

differentially affect the pharmacokinetics of the acid and lactone forms of

simvastatin and atorvastatin. Clinical Pharmacology and Therapeutics, 2008,

84(4), 457-461.

Khatri.G. R.; Frieden, T.R. Controlling tuberculosis in India. New England Journal of

Medicine 2002, 347, 1420-1425.

Kiani, A.; Kohne, C. H.; Franz, T.; Passauer, J.; Haufe, T.; Gross, P.; Ehninger, G.;

Schleyer, E. Pharmacokinetics of gemcitabine in a patient with end-stage renal

References

198


India, 2013

disease: effective clearance of its main metabolite by standard hemodialysis

treatment. Cancer Chemotherapy and Pharmacology 2003, 51, 266-270.

Kikuta, S.; Asakage, T.; Nakao, K.; Sugasawa, M.; Kubota, A. The aggravating

factors of hyperammonemia related to 5-flurouracil infusion- A report of two

cases. Auris Nasus Larynx 2008, 35(2), 295-299.

Kim, R. B.; Leake, B. F.; Choo, E. F.; Dresser, G. K.; Kubba, S. V.; Schwartz, U. I.;

Taylor, A,; Xie, H. G.; McKinsey, J.; Zhou, S.; Lan, L.B.; Schuetz, J. D.;

Schuetz, E. G.; Wilkinson, G. R. Identification of functionally variant MDR1

alleles among European Americans and African Americans. Clinical

Pharmacology and Therapeutics 2001, 70, 189-199.

King, A. E.; Ackley, M. A.; Cass, C. E.; Young, J. D.; Baldwin, S. A. Nucleoside

transporters: from scavengers to novel therapeutic targets. Trends in

Pharmacological Sciences 2006, 27(8), 416-425.

Kirch, H. C.; Schroder, J.; Hoppe, H.; Esche, H.; Seeber, S.; Schutte, J. Recombinant

gene products of two natural variants of the human cytidine deaminase gene

confer different deamination rates of cytarabine invitro. Experimental

Hematology 1998, 26, 421-425.

Klein, T. E.; Altman, R. B.; Eriksson, N.; Gage, B. F.; Kimmel, S. E.; Lee, M. T.;

Limdi, N. A.; Page, D.; Roden, D. M.; Wagner, M. J.; Caldwell, M. D.;

Johnson, J. A. Estimation of the warfarin dose with clinical and

pharmacogenetic data. New England Journal of Medicine 2009, 360, 753-764.

Kouwaki, M.; Hamajima, N.; Sumi, S.; Nonaka, M.; Sasaki, M.; Dobashi, K.;

Kidouchi, K.; Togari, H.; Wada, Y. Identification of novel mutations in the

Dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-

fluorouracil toxicity. Clinical Cancer Research 1998, 4, 2999-3004.

Krishnan, P.; Gullen, E. A.; Lam, W.; Dutschman, G. E.; Grill, S. P.; Cheng, Y. C.

Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation

of L-nucleoside analogs, a new class of anticancer and antiviral agents. Journal

of Biological Chemistry 2003, 278, 36726-36732.

Krynetski, E. Y.; Evans, W. E. Pharmacogenetics as a molecular basis for

individualized drug therapy: The thiopurine S-methyltransferase paradigm.

Pharmaceutical Research 1999, 16, 342-249.

Krynetski, E. Y.; Schuetz, J. D.; Galpin, A. J.; Pui, C. H.; Relling, M. V.; Evans, W.

A single point mutation leading to loss of catalytic activity in human thiopurine

S-methyltransferase. Proceedings of the National Academy of Sciences of the

United States of America 1995, 92, 949-953.

Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J.; Watkins, P. B.; Daly,

A.; Wrighton, S. A.; Hall, S. D.; Maurel, P.; Relling, M.; Brimer, C.; Yasuda,

K.; Venkatramanan, R.; Strom, S.; Thummel, K.; Boguski, M. S.; Schuetz, E.

References

199


India, 2013

Sequence diversity in CYP3A promoters and characterization of genetic basis

for polymorphic CYP3A5 expression. Nature Genetics 2001, 27, 383-391.

Kuiper, G. G.; Enmark, E.; Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J. A. Cloning

of a novel receptor expressed in rat prostrate and ovary. Proceedings of the

National Academy of Sciences of the United States of America 1996, 93(12),

5925-5930.

Kukhanova, M.; Liu, S. H.; Mozzherin, D.; Lin, T. S.; Chu, C. K.; Cheng, Y. C. L-

and D- enantiomers of 2’,3’-dideoxycytidine 5’-triphosphate analogs as

substrates for human DNA polymerases. Implications for the mechanism of

toxicity. The Journal of Biological Chemistry 1995, 290, 23055-23059.

Kukongviriyapan, V.; Prawan, A.; Tassaneyakul, W.; Aiemsa-Ard, J.; Warasiha, B.

Arylamine N-acetyltransferase-2 genotypes in Thai population. British Journal

of Clinical Pharmacology 2003, 55, 278-281.

Kunz, C.; Focke, F.; Saito, Y.; Schuermann, D.; Lettieri, T.; Selfridge, J.; Schar, P.

Base excision by thymine DNA glycosylase mediates DNA-directed

cytotoxicity of 5-flurouracil. PLoS Biology 2009, 7(4), e91.

Kurabayashi, T.; Matsushita, H.; Kato, N.; Nagata, H.; Kikuchi, M.; Tomita, M.;

Yahata, T.; Honda, A.; Tanaka, K. Effect of vitamin D receptor and estrogen

receptor gene polymorphism on the relationship between dietary calcium and

bone mineral density in Japanese women. Journal of Bone and Mineral

Metabolism 2004, 22(2), 139-147.

Lahaye, M.; Rochas, C. Chemical structure and physico-chemical properties of agar.

Hydrobiologia 1991, 221, 137-148.

Larussa, T.; Suraci, E.; Lentini, M.; Nazionale, I. ; Gallo, L. ; Abenavoli, L. ; Imeneo,

M. ; Costanzo, F. S. ; Cuda, G.; Luzza, F. High prevalence of polymorphism

and low activity of thiopurine methyltransferase in patients with inflammatory

bowel disease. European Journal of Internal Medicine 2012, 23, 273-277.

Lee, C. P.; de Jonge, M. J.; O’Donnell, A. E.; Schothorst, K. L.; Hanwell, J.; Chick, J.

B.; Brooimans, R. A.; Adams, L. M.; Drolet, D. W.; de Bono, J. S.; Kaye, S. B.;

Judson, I. R.; Verweij, J. A phase I study of a new nucleoside analogue, OSI-

7836, using two administration schedules in patients with advanced solid

malignancies. Clinical Cancer Research 2006, 12, 2841-2848.

Lee, S. Y.; Lee, A. K.; Ki, C. S.; Kwon, O. J.; Kim, H. J.; Chung, M. P.; Suh, G. Y.;

Kim, J. W. Complete sequencing of a genetic polymorphism in NAT2 in the

Korean population. Clinical Chemistry 2002, 48, 775-777.

Lennard, L.; Cartwright, C. S.; Wade, R.; Richards, S. M.; Vora, A. Thiopurine

methyltransferase genotype-phenotype discordance, and thiopurine active

metabolite formation, in childhood acute lymphoblastic leukemia. British

Journal of Clinical Pharmacology 2012 [Article in press].

References

200


India, 2013

Li, T.; Chang, C. Y.; Jin, D. Y.; Lin, P. J.; Khvorova, A.; Stafford, D. W.

Identification of the gene for vitamin K epoxide reductase. Nature 2004, 427,

541-544.

Liggett, S. B. Polymorphisms of adrenergic receptors: Variations on a theme. Assay

and Drug Development Technologies 2003, 1, 317-326.

Lin, H. J.; Han, C. Y.; Lin, B. K.; Hardy, S. Slow acetylator mutations in the human

polymorphic N- acetyltransferase gene in 786 Asians, blacks, Hispanics and

whites: application to metabolic epidemiology. American Journal of Human

Genetics 1993, 52, 827-834.

Liu, J. J.; Liu, J. L.; Zhang, X.; Xie, L.; Zeng, J. A meta-analysis of the association of

glutathione S-transferase P1 gene polymorphism with the susceptibility of

breast cancer. Molecular Biology Reports 2013 [Article in press].

Loewen, S. K.; Ng, A. M.; Yao, S. Y.; Cass, C. E.; Baldwin, S. A.; Young, J. D.

Identification of amino acid residues responsible for the pyrimidine and purine

nucleoside specificities of human concentrative Na(+) nucleoside cotransporters

hCNT1 and hCNT2. The Journal of Biological Chemistry 1999, 274, 24475-

24484.

Loktionov, A.; Moore, W.; Spencer, S. P.; Vorster, H.; Nell, T.; O’Neill, I. K.;

Bingham, S. A.; Cummings, J. H. Differences in N-acetylation genotypes

between Caucasians and black South Africans: implications for cancer

prevention. Cancer Detection and Prevention Journal 2002, 26, 15-22.

Longley, D. B.; Harkin, D. P.; Johnston, P. G. 5-flurouracil mechanism of action and

clinical strategies. Nature Reviews Cancer 2003, 3(5), 330-338.

Lord, R. S.; Bongiovanni, B.; Bralley, J. A. Estrogen metabolism and the diet-cancer

connection: rationale for assessing the ratio of urinary hydroxylated estrogen

metabolites. Alternative Medicine Review 2002, 7, 112-129.

Lupas, A.; Van Dyke, M.; Stock, J. Predicting coiled coils from protein sequences.

Science 1991, 252, 1162-1164.

Lu, Z. H.; Zhang, R. W.; Diasio, R. B. Dihydropyrimidine dehydrogenase-activity in

human peripheral-blood mononuclear-cells and liver: population characteristics,

newly identified deficient patients and clinical implication in 5-flurouracil

chemotherapy. Cancer Research 1993, 53, 5433-5438.

Lu, Z. H.; Zhang, R.; Diasio, R. B. Purification and characterization of

dihydropyrimidine dehydrogenase from human liver. The Journal of Biological

Chemistry 1992, 267(24), 17102-17109.

References

201


India, 2013

Mackey, J. R.; Baldwin, S. A.; Young, J. D.; Cass, C. E. Nucleoside transport and its

significance for anticancer drug resistance. Drug Resistance Updates 1998, 1,

310-324.

Mackey, J. R.; Yao, S. Y.; Smith, K. M.; Karpinski, E.; Baldwin, S. A.; Cass, C. E.;

Young, J. D. Gemcitabine transport in xenopus oocytes expressing recombinant

plasma membrane mammalian nucleoside transporters. Journal of the National

Cancer Institute 1999, 91, 1876-1881.

MacQueen, D. A.; Heckman, B. W.; Blank, M. D.; Janse Van Rensburg, K.; Park, J.

Y.; Drobes, D. J.; Evans, D. E. Variation in the α 5 nicotinic acetylcholine

receptor gene predicts cigarette smoking intensity as a function of nicotine

content. The Pharmacogenomics Journal 2013 [Article in press].

Maekawa, K.; Saeki, M.; Saito, Y.; Ozawa, S.; Kurose, K.; Kaniwa, N.; Kawamoto,

M.; Kamatani, N.; Kato, K.; Hamaguchi, T.; Yamada, Y.; Shirao, K.; Shimada,

Y.; Muto, M.; Doi, T.; Ohtsu, A.; Yoshida, T.; Matusumura, Y.; Saijo, N.;

Sawada, J. Genetic variations and haplotype structures of the DPYD gene

encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic

differences. Journal of Human Genetics 2007, 52, 804-819.

Magistroni, R.; Manfredini, P.; Furci, L. ; Ligabue, G. ; Martino, C. ; Leonelli, M. ;

Scapoli, C. ; Albertazzi, A. Epidermal growth factor receptor polymorphism and

autosomal dominant polycystic kidney disease. Journal of Nephrology 2003,

16(1), 110-115.

Mahasneh, A.; Jubaili, A.; El Bateiha, A.; Al-Ghazo, M.; Matalka, I.; Malkawi, M.

Polymorphisms of arylamine N-acetyltransferase 2 and risk of lung and

colorectal cancer. Genetics and Molecular Biology 2012, 35(4), 725-733.

Maher, T. J.; Johnson, D. A. Receptors and drug action. In Principles of medicinal

chemistry, 5th

ed; Williams, D. A.; Lemke, T. L., Ed.; Lippincott Wilkins &

Williams, 2002; pp 86-99.

Mahfouz, R. S.; Jankowska, A.; Ebrahem, Q.; Gu, X.; Visconte, V.; Tabarroki, A.;

Terse, P.; Covey, J.; Chan, K.; Ling, Y.; Engelke, K, J.; Sekeres, M. A.; Tiu, R.;

Maciejewski, J.; Radiovoyevitch, T.; Saunthararajah, Y. Increased CDA

expression/activity in males contributes to decreased cytidine analogue half-life

and likely contributes to worst outcomes with 5-azacytidine or decitabine

therapy. Clinical Cancer Research 2013 [Article in press].

Mahgoub, A.; Idle, J. R.; Dring, L. G.; Lancaster, R.; Smith, R. L. Polymorphic

hydroxylation of debrisoquine in man. Lancet 1977, 2, 584-586.

Malik, M. A.; Upadhyay, R.; Modi, D. R.; Zargar, S. A.; Mittal, B. Association of

NAT2 gene polymorphisms with susceptibility to esophageal and gastric cancers

in the Kashmir valley. Archives of Medical Research 2009, 40, 416-423.

References

202


India, 2013

Marc, J. Pharmacogenetics of drug receptors, 7th

ed.; In EFCCC continuous

postgraduate course in clinical chemistry, Dubrovnik, 2007; pp 47-52.

Marinaki, A. M.; Ansari, A.; Duley, J. A.; Arenas, M.; Sumi, S.; Lewis, C. M.;

Shobowale-Bakre, el-M.; Escuredo, E.; Fairbanks, L. D.; Sanderson, J. D.

Adverse drug reactions to azathiopurine therapy are associated with

polymorphisms in the gene encoding inosine triphosphate pyrophosphatase

(ITPase). Pharmacogenetics 2004, 14, 181-187.

Maring, J. G.; van Kuilenburg, A. B.; Haasjes, J.; Piersma, H.; Groen, H. J.; Uges, D.

R.; van Gennip, A. H.; De Vries, E. G. Reduced 5-FU clearance in a patient with

low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.

British Journal of Cancer 2002, 86, 1028–1033.

Maring, J. G.; Wachters, F. M.; Slijfer, M.; Maurer, J. M.; Boezen, H. M.; Uges, D.

R.; de Vries, E. G.; Groen, H. J. Pharmacokinetics of gemcitabine in non-small

cell lung cancer patients: impact of the 79A>C cytidine deaminase

polymorphism. European Journal of Clinical Pharmacology 2010, 66, 611-617.

Markman, M. New, expanded, and modified use of approved antineoplastic agents in

ovarian cancer. Oncologist 2007, 12, 186-190.

Martinez, C.; Agundez, J. A. G.; Olivera, M.; Martin, R.; Ladero, J. M.; Benitez, J.

Lung cancer and mutations at the polymorphic NAT2 gene locus.


Mason, D. A.; Moore, J. D.; Green, S. A.; Liggett, S. B. A gain of functional

polymorphism in a G-protein coupling domain of the human beta-1-adrenergic

receptor. The Journal of Biological Chemistry 1999, 274, 12670-12674.

Matsuda, A.; Nakajima, Y.; Azuma, A.; Tanaka, M.; Sasaki, T. Nucleosides and

nucleotides. 100. 2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofuranosylcytosine

(CNDAC): design of a potencial mechanism-based DNA-strand breaking

antineoplastic nucleoside. Journal of Medicinal Chemistry 1991, 34(9), 2917-

2919.

Matsushita, H.; Kurabayashi, T.; Tomita, M.; Tanaka, K. Effects of vitamin D and

estrogen receptor gene polymorphisms on the changes in lumbar bone mineral

density with multiple pregnancies in Japanese women. Human Reproduction

2003, 19(1), 59-64.

Mattison, L. K.; Soong, R.; Diasio, R. B. Implications of dihydropyrimidine

dehydrogenase on 5-flurouracil pharmacogenetics and pharmacogenomics.

Pharmacogenomics 2002, 3, 485-492.

Maxwell, T. J.; Ameway, M. M.; Pritchard, S.; Thornton, N.; Folayan, G.; Githang`a,

J.; Indalo, A.; Tariq, M.; Mobarek, A.; Evans, D. A.; Ofori-Adjei, D.;

Templeton, A. R.; McLeod, H. L. Beta-2 adrenergic receptor genotypes and

References

203


India, 2013

haplotypes in different ethnic groups. International Journal of Molecular

Medicine 2005, 16, 573-580.

McKibbin, T.; Zhao, W.; Tagen, M.; Daw, N. C.; Furman, W. L.; McGregor, L. M.;

Geyer, J. R.; Allen, J. W.; Stewart, C. F. Epidermal growth factor receptor

polymorphisms and risk for toxicity in paediatric patients treated with geftinib.

European Journal of Cancer 2010, 46(11), 2045-2051.

McLeod, H. L.; Lin, J. S.; Scott, E. P.; Pui, C. H.; Evans, W. E. Thiopurine

methyltransferase activity in American white subjects and black subjects.

Clinical Pharmacology and Therapeutics 1994, 55, 15-20.

McLeod, H. L.; Miller, D. R.; Evans, W. E. Azathiopurine-induced myelosupression

in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993,

341, 1151.

Mdluli, R. A.; Slayden, R. A.; Zhu, Y.; Ramaswamy, S.; Pan, X.; Mead, D.; Crane, D.

D.; Musser, J. M.; Barry, C. E. 3rd

. Inhibition of a Mycobacterium tuberculosis

beta-ketoacyl ACP synthase by isoniazid. Science 1998, 280, 1607-1610.

Mercier, C.; Evrard, A.; Ciccolini, J. Genotype-based methods for anticipating

gemcitabine-related severe toxicities may lead to false-negative results. Journal

of Clinical Oncology 2010, 23, 4855.

Mercier, C.; Raynal, C.; Dahan, L.; Ortiz, A.; Evrard, A.; Dupuis, C.; Blesius, A.;

Duluc, M.; Franceschini, F.; Giacometti, S.; Salas, S.; Milano, G.; Favre, R.;

Seitz, J. F.; Ciccolini, J. Toxic death case in a patient undergoing gemcitabine-

based chemotherapy in relation with cytidine deaminase downregulation.

Pharmacogenetics and Genomics 2007, 17, 841-844.

Metushi, I. G.; Nakagawa, T.; Uetrecht, J. Direct oxidation and covalent binding of

isoniazid to rodent liver and human hepatic microsomes: humans more like mice

than rats. Chemical Research in Toxicology 2012, 25(11), 2567-2576.

Middlebrook, G. Isoniazid-resistance and catalase activity of tubercle bacilli.

American Review of Tuberculosis 1954, 69, 471-472.

Milano, G. A.; Etienne, M. C.; Cassuto-Viguier, E.; Thyss, A.; Santini, J.; Frenay, M.;

Renee, N.; Schneider, M.; Demard F. Influence of sex and age on flurouracil

clearance. Journal of Clinical Oncology 1992, 10, 1171-1175.

Milano, G. A.; Etienne, M. C.; Pierrefite, V.; Barberi-Heyob, M.; Deporte-Fety, R.;

Rene´e, N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-

related toxicity. British Journal of Cancer 1999, 79, 627–630.

Milano, G.; McLeod, H. L. Can dihydropyrimidine dehydrogenase impact 5-

flurouracil- based treatment? European Journal of Cancer 2000, 36, 37-42.

References

204


India, 2013

Miller, S. A.; Dykes, D. D.; Polesky, H. F. A simple salting out procedure for

extracting DNA from human nucleated cells. Nucleic Acid Research 1988, 16,

1215.

Mittal, R. D.; Srivastava, D.; Mandhani, A. NAT2 gene polymorphism in bladder

cancer: A study from North India. International Brazilian Journal of Urology

2004, 30, 279-288.

Mondal, R, Ghosh, S. K.; Talukdar, F. R.; Laskar, R. S. Association of mitochondrial

D-loop mutations with GSTM1 and GSTT1 polymorphisms in oral carcinoma:

A case-control study from Northeast India. Oral Oncology 2012 [Article in

press].

Montero, A.; Gluck, S. Long-term complete remission with nab-paclitaxel,

bevacizumab, and gemcitabine combination therapy in a patient with triple-

negative metastatic breast cancer. Case Reports in Oncology 2012, 5(3), 687-

692.

Morel, A.; Boisdron-Celle, M.; Fey, L.; Soulie, P.; Craipeau, M. C.; Traore, S.;

Gamelin, E. Clinical relevance of different dihydropyrimidine dehydrogenase

gene single nucleotide polymorphisms on 5-flurouracil tolerance. Molecular

Cancer Therapeutics 2006, 5, 2895-2904.

Morton, L. M.; Schenk, M.; Hein, D. W.; Davis, S.; Zahm, S. H.; Cozen, W.; Cerhan,

J. R.; Hartge, P.; Welch, R.; Chanock, S. J.; Rothman, N.; Wang, S. S. Genetic

variation in N-acetyltransferase 1(NAT1) and 2 (NAT2) and risk of non-

hodgkin lymphoma. Pharmacogenetics and Genomics 2006, 16, 537-545.

Mullis, K.B., Faloona F. Specific synthesis of DNA in vitro via a polymerase

catalysed chain reaction. Methods in Enzymology 1987, 155, 335-350.

Murali, M.; Manjari, T.; Madhuri, B.; Raghavan, S.; Jain, D. C.; Vivekanandhan, S.

Genetic polymorphism of NAT2 metabolizing enzymes on phenytoin

pharmacokinetics in Indian epileptic patients developing toxicity. CNS

Neuroscience and Therapeutics 2012, 18(4), 350-358.

Musser, J. M.; Kapur, V.; Williams, D.; Kreisworth, B.; van Soolingen, D.; van

Embden, J. Characterization of the catalase-peroxidase gene (katG), and the

inhA locus in isoniazid resistant and susceptible strains of Mycobacterium

tuberculosis by automated DNA sequencing: restricted array of mutations

associated with drug resistance. The Journal of Infectious Diseases 1996, 173,

196-202.

Naguib, F. N.; El Kouni, M. H.; Cha, S. Enzymes of uracil catabolism in normal and

neoplastic human tissues. Cancer Research 1985, 54, 5405-5412.

Nakamura, T.; Saito, Y.; Murayama, N.; Saeki, M.; Soyama, A.; Sai, K.; Ozawa, S.;

Sawada, J. Apparent low frequency of sequence variability within the proximal

promoter region of the cytochrome P450 (CYP) 3A5 gene in established cell

References

205


India, 2013

lines from Japanese individuals. Biological & Pharmaceutical Bulletin 2001, 24,

954-957.

Nauck, M.; Gierens, H.; Marz, W.; Wieland, H. Rapid detection of a common

Dihydropyrimidine dehydrogenase mutation associated with 5-flurouracil

toxicity and congenital thymine uraciluria using fluorogenic hybridization

probes. Clinical Biochemistry 2001, 34, 103-105.

Nei, M.; Kumar, S. Genetic polymorphism and evolution. In Molecular evolution and

phylogenetics, Oxford Univesity Press Inc: NewYork, 2000; pp 231-262.

Nelson, D. L.; Cox, M. M. Lehninger principles of biochemistry, 4th

ed.; 2004, W.H

Freeman and Company.

Ngo, L. Y.; Patil, S. D.; Unadkat, J. D. Ontogenic and longitudinal activity of Na(+)

nucleoside transporters in human intestine. American Journal of Physiology-

Gastrointestinal and Liver Physiology 2001, 280, G475-G481.

Noble, S.; Goa, K. L. Gemcitabine: A review of its pharmacology and clinical

potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997, 54,

447-452.

Nomura, F.; Lee, K.; Nishikawa, S.; Ito, K.; Yoshimura, K.; Tsuji, Y.; Kawata, R. A

case of hyperammonemia with 5-FU induced encephalopathy. Practica Oto-

Rhino-Laryngologica 2011, 104(3), 223-227.

Oda, A.; Kobayashi, K.; Takahashi, O. Computational study of the three-dimensional

structure of N-acetyltransferase 2-acetyl coenzyme A complex. Biological and

Pharmaceutical Bulletin 2010, 33(10), 1639-1643.

Oguri, K.; Tachi, T.; Matsuoka, T. Visceral fat accumulation and metabolic syndrome

in children : the impact of Try64Arg polymorphism of the beta 3- adrenergic

receptor gene. Acta Pediatrica 2013 [Article in press].

Okasha, Samir. Population genetics, In: The Stanford Encyclopedia of Philosophy, ed:

Zalta, E. N.; Fall 2012 edition.

Okazaki, T.; Javle, M.; Tanaka, M.; Abbruzzese, J. L.; Li, D. Single nucleotide

polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival

and drug toxicity. Clinical Cancer Research 2010, 16, 320-329.

Omura, K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity

in 5-FU based chemotherapy: mutations in the DPD gene, and DPD inhibitory

fluropyrimidines. International Journal of Clinical Oncology 2003, 8, 132-138.

Ostruszka, L. J.; Shewach, D. S. The role of DNA synthesis inhibition in the

cytotoxicity of 2’,2’-difluoro-2’-deoxycytidine. Cancer Chemotherapy and

Pharmacology 2003, 52, 325-332.

References

206


India, 2013

Owen, R. P.; Gray, J. H.; Taylor, T. R.; Carlson, E. J.; Huang, C. C.; Kawamoto, M.;

Johns, S. J.; Stryke, D.; Ferrin, T. E.; Giacomini, K. M. Genetic analysis and

functional characterization of polymorphisms in the human concentrative

nucleoside transporter, CNT2. Pharmacogenetics and Genomics 2005, 15, 83-

90.

Paabo, S. The mosaic that is our genome. Nature 2003, 421, 409-412.

Pare, L.; Paez, D.; Salazar, J.; Elisabeth, R.; Tizzano, E.; Marcuello, E.; Baiget, M.

Absence of large intragenic rearrangements in the DPYD gene in a alrge cohort

of coloirectal cancer patients treated with 5-Fu based chemotherapy. British

Journal of Clinical Pharmacology 2010, 70(2), 268-272.

Parker, W. B. Enzymology of purine and pyrimidine antimetabolites used in the

treatment of cancer. Chemical Reviews 2009, 109, 2880-2893.

Parkin, D. P.; Vandelplas, S.; Botha, F. J. Trimodality of isoniazid elimination:

phenotype and genotype in patients with tuberculosis. American Journal of

Respiratory and Critical Care Medicine 1997, 155, 1712-1722.

Parsons, W. D.; Jones, S.; Zhang, X.; Ho Lin, J. C.; Leary, R. J.; Angenendt, P.;

Mankoo, P.; Carter, H.; Sui, I. M.; Gallia, G. L.; Olivi, A.; McLendon, R.;

Rasheed, B. A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D. A.; Tekleab,

H.; Diaz Jr, L. A.; Hartigan, J.; Smith, D. R.; Strausberg, R. L.; Marie, S. K. N.;

Shinjo, S. M. O.; Yan, H.; Riggins, G. J.; Bigner, D. D.; Karchin, R.;

Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K.

W. An integrated genomic analysis of human glioblastoma multiforme. Science

2008, 321, 1807-1812.

Paskind, H. A. Some differences in response to atropine in white and coloured races.

Journal of American Medical Association 1921, 76, 104-108.

Patin, E.; Barreiro, L. B.; Sabeti, P. C.; Austerlitz, F.; Luca, F.; Sajantila, A.; Behar,

D. M.; Semino, O.; Sakuntabhai, A.; Guiso, N.; Gicquel, B.; McElreavey, K.;

Harding, R. M.; Heyer, E. Deciphering the ancient and complex evolutionary

history of human arylamine N-acetyltransferase genes. American Journal of

Human Genetics 2006a, 78, 423-436.

Patin, E.; Harmant, C.; Kidd, K. K.; Kidd, J.; Froment. A.; Mehdi, S. Q.; Sica, L.;

Heyer, E.; Quintana-Murci, L. Sub-Saharan African coding sequence variation

and haplotypes diversity at the NAT2 gene. Human Mutation 2006b, 27, 720.

Paugh, S. W.; Stocco, G.; Evans, W. E. Pharmacogenomics in pediatric leukemia.

Current Opinion in Pediatrics 2010, 22, 703-710.

Pavlakis, N.; Bell, D. R.; Millward, M. J.; Levi, J. A. Fatal pulmonary toxicity

resulting from treatment with gemcitabine. Cancer 1997, 80, 286-291.

References

207


India, 2013

Peters, G. J.; Pinedo, H. M.; Ferwerda, W.; de Graff, T. W.; van Dijk, W. Do

antimetabolites interfere with the glycosylation of cellular glycoconjugates?

European Journal of Cancer 1990, 26, 516-523.

Philips, H. A.; Favre, I.; Kirkpatrick, M.; Zuberi, S.M.; Goudie, D.; Heron, S. E.;

Scheffer, I. E.; Sutherland, G. R.; Berkovic, S. F.; Bertrand, D.; Mulley, J. C.

CHRNB2 is the second acetylcholine receptor subunit associated with

autosomal dominant nocturnal frontal lobe epilepsy. American Journal of

Human Genetics 2001, 68, 225-231.

Plunkett, W.; Huang, P.; Gandhi, V. Preclinical characteristics of gemcitabine.

Anticancer drugs 1995a, 6, S7-S13 (supp 6).

Plunkett, W.; Huang, P.; Searcy, C. E.; Gandhi, V. Gemcitabine: preclinical

pharmacology and mechanisms of action. Seminars in Oncology 1996, 23, 3-15.

Plunkett, W.; Huang, P.; Xu, Y. Z.; Heinemann, V.; Grunewald, R.; Gandhi, V.

Gemcitabine: metabolism, mechanism of action, and self-potentiation. Seminars

in Oncology 1995b, 22, 3-10.

Pui, C. H.; Evans, W. E. Treatment of acute lymphoblastic leukemia. New England

Journal of Medicine 2006, 354, 166-178.

Raida, M.; Schwabe, W.; Hausler, P.; van Kuilenburg, A. B.; van Gennip, A. H.;

Behnke, D.; Hoffken, K. Prevalence of a common point mutation in the

dihydropyrimidine dehydrogenase (DPD) gene within the 5’-splice donor site of

intron 14 in patients with severe 5-flurouracil (5-FU)- related toxicity compared

with controls. Clinical Cancer Research 2001, 7, 2832-2839.

Rathz, D. A.; Brown, K. M.; Kramer, L. A.; Liggett, S. B. Amino acid 49

polymorphisms of the human beta-1-adrenergic receptor affect agonist promoted

trafficking. Journal of Cardiovascular Pharmacology 2002, 39, 155-160.

Raynal, C.; Ciccolini, J.; Mercier, C.; Boyer, J. C.; Polge, A.; Lallemant, B.; Mouzat,

K.; Lumbroso, S.; Brouillet, J. P.; Evrard, A. High-resolution melting analysis

of sequence variations in the Cytidine deaminase gene (CDA) in patients treated

with gemcitabine. Therapeutic Drug Monitoring 2010, 32, 53-60.

Rebbeck, T. R.; Jaffe, J. M.; Walker, A. H.; Wein, A. J.; Malkowicz, S. B.

Modification of clinical presentation of prostrate tumors by a novel genetic

variant in CYP3A4. Journal of the National Cancer Institute 1998, 90(16),

1225-1229.

Regoes, R. R. Population genetics meets cancer genomics. Proceedings of the

National Academy of Sciences of the United States of America 2010, 107(43),

18241-18242.

References

208


India, 2013

Reihsaus, E.; Innis, M.; Macintyre, N.; Liggett, S. B. Mutations in the gene encoding

for the β2-adrenergic receptor in normal and asthmatic patients. American

Journal of Respiratory Cell and Molecular Biology 1993, 8, 334-339.

Report on tuberculosis and HIV in India- The challenges ahead. New England Journal

of Medicine 2007, 356, 1198-1199.

Riddle, B.; Jencks, W. P. Acetyl-coenzyme A: arylamine N-acetyltransferase. Role of

the acetyl-enzyme intermediate and the effects of substituents on the rate. The

Journal of Biological Chemistry 1971, 246, 3250-3258.

Ridge, S. A.; Sludden, J.; Brown, O.; Robertson, L.; Wei, X.; Sapone, A.; Fernandez-

Salguero, P. M.; Gonzalez, F. J.; Vreken, P.; van Kuilenburg, A. B.; van Gennip,

A. H.; McLeod, H. L. Dihydropyrimidine dehydrogenase pharmacogenetics in

Caucasian subjects. British Journal of Clinical Pharmacology 1998, 46, 151-

156.

Rieder, M. J.; Reiner, A. P.; Gage, B. F.; Nickerson, D. A.; Eby, C. S.; McLeod, H.

L.; Blough, D. K.; Thummel, K. E.; Veenstra, D. L.; Rettie, A. E. Effect of

VKORC1 haplotypes on transcriptional regulation and warfarin dose. New

England Journal of Medicine 2005, 352, 2285-2293.

Ritzel, M. W.; Yao, S. Y.; Huang, M. Y.; Elliott, J. F.; Cass, C. E.; Young, J. D.

Molecular cloning and functional expression of cDNAs encoding a human

NA+-nucleoside cotransporter (hCNT1). American Journal of Physiology 1997,

272, C707-C714.

Ritzel, M. W.; Yao, S. Y.; Ng, A. M.; Mackey, J. R.; Cass, C. E.; Young, J. D.

Molecular cloning, functional expression and chromosomal localization of a

cDNA encoding a human Na+ / nucleoside cotransporters (hCNT2) selective for

purine nucleosides and uridine. Molecular Membrane Biology 1999, 15, 203-

211.

Rodrigues, L.; Machado, D.; Couto, I.; Amaral, L.; Viveiros, M. Contribution of

efflux activity to isoniazid resistance in the Mycobacterium tuberculosis

complex. Infection, Genetics and Evolution 2012, 12(4), 695-100.

Rogers, J. F.; Nafziger, A. N.; Bertino, J. S. Jr. Pharmacogenetics affects dosing,

efficacy and toxicity of cytochrome P450-metabolized drugs. American Journal

of Medicine 2002, 113, 746-750.

Rouse, D. A.; Li, Z.; Bai, G. H.; Morris, S. L. Characterization of the KatG and inhA

genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis.

Antimicrobial Agents and Chemotherapy 1995, 39(11), 2472-2477.

Rozwarski, D. A.; Grant, G. A.; Barton, D. H. R.; Jacobs, W. R.; Sachettini, J. C.

Modification of the NADH of the isoniazid target (inhA) from Mycobacterium

tuberculosis. Science 1998, 279, 98-102.

References

209


India, 2013

Ryan, J.; Canonico, M.; Carcaillon, L.; Carriere, I.; Scali, J.; Dartigues, J-F.; Dufouli,

C.; Ritchie, K.; Scarabin, P-Y.; Ancelin, M-L. Hormone treatment, estrogen

receptor polymorphisms and mortality: A prospective cohort study. PLoS ONE

2012, 7(3), e34112.

Saccone, S.; Besati, C.; Andreozzi, L.; Della Valle, G.; Garattini, E.; Terao, M.

Assignment of the human Cytidine deaminase (CDA) gene to chromosome 1

band p35-p36.2. Genomics 1994, 22, 661-662.

SACGHS report: Realizing the potential of Pharmacogenomics: Opportunities and

Challenges. Report of the Secretary’s Advisory committee on Genetics, Health

and Society, USA. May 2008.

Saiki, R. A.; Gelfand, D. H.; Stoffel, S.; Scharf, S.; Higuchi, R. H.; Horn, G. T.;

Mullis, K. B.; Erlich, H. A. Primer-directed enzymatic amplification of DNA

with a thermostable DNA polymerase. Science 1988, 239, 487-491.

Sampath, D.; Rao, V. A.; Plunkett, W. Mechanisms of apoptosis induction by

nucleoside analogues. Oncogene 2003, 22, 9603-9074.

Sandy, J.; Mushtaq, A.; Holton, S. J.; Schartau, P.; Noble, M. E. M.; Sim, E.

Investigation of the catalytic triad of arylamine N-acetyltransferases: essential

residues required for acetyl-transfer for arylamines. Biochemical Journal 2005,

390, 115-123.

Sanger, F.; Coulson, A. R. A rapid method for determining sequences in DNA by

primed synthesis with DNA polymerase. Journal of Molecular Biology 1975,

94, 441-448.

Sanger, F.; Nicklen, S.; Coulson, A. R. DNA sequencing with chain-terminating

inhibitors. The proceedings of the National Academy of Sciences of the United

States of America 1977, 74, 5463-5467.

Santos, F. R.; Magno, L. A. V. Pharmacogenomics and Metabolism: Past, Present and

Future. In Topics on drug metabolism, Dr. James Paxton (ed).; 2012, ISBN:

978-953-51-0099-7, InTech, available from

http://www.intechopen.com/books/topics-on-drug-

metabolism/pharmacogenetics-and-metabolism-past-present-and-future.

Schnackerz, K. D.; Dobritzsch, D.; Lindgvist, Y.; Cook, P. F. Dihydropyrimidine

dehydrogenase: a flavoprotein with four iron-sulfur clusters. Biochimica et

Biophysica Acta 2004, 170(1-2), 61-74.

Schwab, M.; Zanger, U. M.; Marx, C.; Schaeffeler, E.; Klein, K.; Dippon, J.; Kerb,

R.; Blievernicht, J.; Fischer, J.; Hofmann, U.; Bokemeyer, C.; Eichelbaum, M.

German 5-FU toxicity study group. Role of genetic and nongenetic factors for

fluorouracil treatment-related severe toxicity: a prospective clinical trail by the

German 5-FU toxicity study group. Journal of Clinical Oncology 2008, 26,

2131-2138.

http://www.intechopen.com/books/topics-on-drug-metabolism/pharmacogenetics-and-metabolism-past-present-and-future

http://www.intechopen.com/books/topics-on-drug-metabolism/pharmacogenetics-and-metabolism-past-present-and-future

References

210


India, 2013

Sebastiani, V.; Ricci, F.; Rubio-Viqueira, B.; Kulesza, P.; Yeo, C. J.; Hidalgo, M.;

Klein, A.; Laheru, D.; Lacobuzio-Donahue, C. A. Immunohistochemical and

genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to

molecular mechanisms of gemcitabine resistance and survival. Clinical Cancer

Research 2006, 12(8), 2492-2497.

Seck, K.; Riemer, S.; Kates, R.; Ullrich, T.; Lutz, V.; Karbeck, N.; Schmitt, M.;

Kiechle, M.; Diasio, R.; Gross, E. Analysis of the DPYD gene implicated in 5-

flurouracil catabolism in a cohort of Caucasian individuals. Clinical Cancer

Research 2005, 11, 5886-5892.

Shin, J. G. Ethnic differences of two non-synonymous single nucleotide

polymorphisms in CDA gene. Drug Metabolism and Pharmacokinetics 2009,

24, 553-556.

Sim, S. C.; Ingelman-Sundberg, M. The Human Cytochrome P450 (CYP) Allele

Nomenclature Website: a peer reviewed database of CYP variants and their

associated effects. Human Genomics 2010, 4, 278-281.

Sinclair, J. C.; Sandy, J.; Delgoda, R.; Sim, E.; Noble, M. E. Structure of arylamine

N-acetyltransferase reveals a catalytic triad. Nature Structural & Molecular

Biology 2000, 7, 560-564.

Singh, N.; Dubey, S.; Chinnaraj, S.; Golani, A.; Maitra, A. Study of NAT2 gene

polymorphisms in an Indian population. Association of plasma isoniazid

concentration in a cohort of tuberculosis patients. Molecular Diagnosis &

Therapy 2009, 13, 49-58.

Smith, K. M.; Ng, A. M.; Yao, S. Y.; Labedz, K. A.; Knaus, E. E.; Wiebe, L. I.; Cass,

C. E.; Baldwin, S. A.; Chen, X. Z.; Karpinski, E.; Young, J. D.

Electrophysiological characterization of a recombinant human Na+-coupled

nucleoside transporter (hCNT1) produced in xenopus oocytes. The Journal of

Physiology 2004, 558, 807-823.

Sobrero, A. F.; Aschele, C.; Bertino, J. R. Flurouracil in colorectal cancer – a tale of

two drugs: implications for biochemical modulation. Journal of Clinical

Oncology 1997, 15, 368-381.

Sobti, R. C.; Kaur, P.; Kaur, S.; Janmeja, A. K.; Jindal, S. K.; Kishan, J.; Sara, R.

Impact of interaction of polymorphic forms of p53 codon 72 and N-acetylation

gene (NAT2) on the risk of lung cancer in the North Indian population. DNA

and Cell Biology 2009, 28, 1-7.

Someya, H.; Shaddix, S. C.; Tiwari, K. N.; Secrist, J. A. III; Parker, W. B.

Phosphorylation of 4’-thio-beta-D-arabinofuranosylcytosine and its analogs by

human deoxycytidine kinase. Journal of Pharmacology and Experimental

Therapeutics 2003, 304, 1314-1322.

References

211


India, 2013

Soo, R. A.; Wang, L. Z.; Ng, S. S.; Chong, P. Y.; Yong, W. P.; Lee, S. C.; Liu, J. J.;

Choo, T. B.; Tham, L. S.; Lee, H. S.; Goh, B. C.; Soong, R. Distribution of

gemcitabine pathway genotypes in ethnic Asians and their association with

outcome in non-small cell lung cancer patients. Lung Cancer 2009, 63, 121-127.

Spratlin, J.; Sangha, R.; Glubrecht, D.; Dabbagh, L.; Young, J. D.; Dumontet, C.;

Cass, C.; Lai, R.; Mackey, J. R. The absence of human equilibrative nucleoside

transporter 1 is associated with reduced survival in patients with gemcitabine-

treated pancreas adenocarcinoma. Clinical Cancer Research 2004, 10(20),

6956-6961.

Stephens, M.; Donnelly, P. A. Comparison of Bayesian methods for haplotype

reconstruction from population genotype data. American Journal of Human

Genetics 2003, 73, 1162- 1169.

Stephens, M.; Scheet, P. Accounting for decay of linkage disequilibrium in haplotype

inference and missing data imputation. American Journal of Human Genetics

2005, 76, 449-462.

Stephens, M.; Smith, N. J.; Donnelly, P. A new statistical method for haplotype

reconstruction from population data. American Journal of Human Genetics

2001, 68, 978-989.

Stocco, G.; Cheok, M. H.; Crews, K. R.; Dervieux, T.; French, D.; Pei, D.; Yang, W.;

Cheng, C.; Pui, C. H.; Relling, M. V.; Evans, W. E. Genetic polymorphism of

inosine triphosphate pyrophosphatase is a determinant of mercaptopurine

metabolism and toxicity during treatment for acute lymphoblastic leukemia.

Clinical Pharmacology and Therapeutics 2009, 85, 164-172.

Stocco, G.; Crews, K. R.; Evans, W. E. Genetic polymorphism of inosine-

triphosphate-pyrophosphatase influences mercaptopurine metabolism and

toxicity during treatment of acute lymphoblastic leukemia individualized for

thiopurine S-methyltransferase status. Expert Opinion on Drug Safety 2010, 9,

23-37.

Stocco, G.; Franca, R.; Verzegnassi, F.; Londero, M.; Rabusin, M.; Decorti, G.

Multilocus genotypes of relevance for drug metabolizing enzymes and therapy

with thiopurines in patients with acute lymphoblastic leukemia. Frontiers in

Genetics 2013, 3(309), 1-9.

Stoehlmacher-Williams, J.; Obermann, L.; Ehninger, G.; Goekkurt, E. Polymorphisms

of the epidermal growth factor receptor (EGFR) and survival in patients with

advanced cancer of the head and neck (HNSCC). Anticancer Research 2012,

32(2), 421-425.

Subbarayan, P. R.; Sarkar, M.; Nelson, G.; Benitez, E.; Singhal, S.; Ardalan, B.

Chronic exposure of colorrectal cancer cells in culture to fluropyrimidine

analogs induces thymidylate synthase and suppresses p53. A molecular

explanation for 5-FU resistance. Anticancer Research 2010, 30(4), 1149-1156.

References

212


India, 2013

Sugiyama, E.; Kaniwa, N.; Kim, S. R.; Hasegawa, R.; Saito, Y.; Ueno, H.; Okusaka,

T.; Ikeda, M.; Morizane, C.; Konda, S.; Yamamoto, N.; Tamura, T.; Furuse, J.;

Ishii, H.; Yoshida, T.; Saijo, N.; Sawada, J. Population pharmacokinetics of

gemcitabine and its metabolites in Japanese cancer patients: impact of genetic

polymorphisms. Clinical Pharmacokinetics 2010, 49, 549-558.

Sugiyama, E.; Kaniwa, N.; Kim, S. R.; Kikura-Hanajiri, R.; Hasegawa, R.; Maekawa,

K.; Saito, Y.; Ozawa, S.; Sawada, J.; Kamatani, N.; Furuse, J.; Ishii, H.;

Yoshida, T.; Ueno, H.; Okusaka, T.; Saijo, N. Pharmacokinetics of gemcitabine

in Japanese cancer patients: the impact of cytidine deaminase polymorphism.

Journal of Clinical Oncology 2007, 25, 32-42.

Sugiyama, E.; Lee, S. J.; Lee, S. S.; Kim, W. Y.; Kim, S. R.; Tohkin, M.; Hasegawa,

R.; Okuda, H.; Kawamoto, M.; Kamatani, N.; Sawada, J.; Kaniwa, N.; Saito, Y.;

Shin, J. G. Ethnic differences of two non-synonymous single nucleotide

polymorphisms in CDA gene. Drug Metabolism and Pharmacokinetics 2009,

24, 553-556.

Sun, Z. F.; Zhang, J.; Xu, H. M.; Wang, G. L.; Dong, P. Association between GSTM1

polymorphism and nasopharyngeal cancer susceptibility: A meta-analysis.

Asian Pacific Journal of Cancer Prevention 2012, 13(11), 5817-5821.

Tai, H. L.; Krynetski, E. Y.; Schuetz, E. G.; Yanishevski, Y.; Evans, W. E. Enhanced

proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles

in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of

TPMT activity. Proceedings of the National Academy of Sciences of the United

States of America 1997, 94, 6444-6449.

Tai, H. L.; Krynetski, E. Y.; Yates, C. R.; Loennechen, T.; Fessing, M.; Krynetskaia,

N. F.; Evans, W. E. Thiopurins S-methyltransferase deficiency: two nucleotide

transitions define the most prevalent mutant allele associated with loss of

catalytic activity in Caucasians. American Journal of Human Genetics 1996, 58,

694-702.

Takai, S.; Kimura, S.; Gonzalez, F. J.; Yamada, K. Assignment of the human

dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by

fluorescence in situ hybridisation. Genomics 1994, 24, 613-614.

Takayama, K.; Wang, L.; David, H. L. Effect of isoniazid on the in vivo mycolic acid

synthesis, cell growth, and viability of Mycobacterium tuberculosis.

Antimicrobial Agents and Chemotherapy 1972, 2, 29-35.

Takechi, T.; Okabe, H.; Fujioka, A.; Murakami, Y.; Fukushima, M. Relationship

between protein levels and gene expression of dihydropyrimidine

dehydrogenase in human tumor cells during growth in culture and in nude mice.

Japan Journal of Cancer Research 1998, 89, 1144–1153.

Takimoto, C. H.; Yee, L. K.; Venzon, D. J.; Schuler, B.; Grollman, F.; Chabuk, C.;

Hamilton, J. M.; Chen, A. P.; Allegra, C. J.; Grem, J. L. High inter- and

References

213


India, 2013

intrapatient variation in 5- flurouracil plasma concentrations during a prolonged

drug infusion. Clinical Cancer Research 1999, 5, 1347-1352.

Talbot, J.; Magno, L. A.; Santana, C. V.; Sousa, S. M.; Melo, P. R.; Correa, R. X.; Di

Pjetro, G.; Rios-Santos, F. Interethnic diversity of NAT2 polymorphisms in

Brazilian admixed populations. BMC Genetics 2010, 11, 87.

Tanaka, T.; Ikeda, M.; Okusaka, T.; Ueno, H.; Morizane, C.; Hagihara, A.; Iwasa, S.;

Kojima, Y. Prognostic factors in Japanese patients with advanced pancreatic

cancer treated with single-agent gemcitabine as first line therapy. Japan Journal

of Clinical Oncology 2008, 38, 755-761.

Tanaka-Nozaki, M.; Onda, M.; Tanaka, N.; Kato, S. Variations in 5-fluorouracil

concentrations of colorectal tissues as compared with dihydropyrimidine

dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels.

Clinical Cancer Research 2001, 7, 2783–2787.

Tavridou, A.; Petridis, I.; Vasileiadis, M.; Ragia, G.; Heliopoulos, I.; Vargemezis, V.;

Manolopoulos, V. G. Association of VKORC1 -1639G>A polymorphism with

carotid intima- media thickness in type 2 diabetes mellitus. Diabetes Research

and Clinical Practice 2011, 94(2), 236-241.

Tayeb, M. T.; Clark, C.; Sharp, L.; Haites, N. E.; Rooney, P. H.; Murray, G. I.; Payne,

S. N.; McLeod, H. L. CYP3A4 promoter variant is associated with prostrate

cancer risk in men with benign prostrate hyperplasia. Oncology Reports 2002,

9(3), 653-655.

Taylor, M. R. Pharmacogenetics of human beta-adrenergic receptors.

The Pharmacogenomics Journal 2007, 7, 29-37.

Teh, L. K.; Hashim, H.; Zakaria, Z. A.; Salleh, M. Z. Polymorphisms of UGT1A1*6,

UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia. The

Indian Journal of Medical Research 2012, 136, 249-259.

Teh, L. K.; Ismail, R.; Yusoff, R.; Hussein, A.; Isa, M. N.; Rahman, A. R.

Heterogeneity of the CYP2D6 gene among Malays in Malaysia. Journal of

Clinical Pharmacy and Therapeutics 2001, 26, 205-211.

Tibaldi, C.; Giovannetti, E.; Vasile, E.; Mey, V.; Laan, A. C.; Nannizzi, S.; Di

Marsico, R.; Antonuzzo, A.; Orlandini, C.; Ricciardi, S.; Del Tacca, M.; Peters,

G. J.; Falcone, A.; Danesi, R. Correlation of CDA, ERCC1, and XPD

polymorphisms with response and survival in gemcitabine/cisplatin-treated

advanced non-small cell lung cancer patients. Clinical Cancer Research 2008,

14, 1797-1803.

Toyama, Y.; Yoshida, S.; Saito, R.; Kitamura, H.; Okui, N.; Miyake, R.; Ito, R.; Son,

K.; Usuba, T.; Nojiri, T.; Yanaga, K. Successful adjuvant bi-weekly gemcitabine

chemotherapy for pancreatic cancer without impairing patients quality of life.

World Journal of Surgical Oncology 2013, 11(1), 3.

References

214


India, 2013

Tsume, Y.; Amidon, G. L. The feasibility of enzyme targeted activation for amino

acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential

targeted enzyme. Molecules 2012, 17(4), 3672-3689.

Ueno, H.; Kaniwa, N.; Okusaka, T.; Ikeda, M.; Morizane, C.; Kondo, S.; Sugiyama,

E.; Kim, S. R.; Hasegawa, R.; Saito, Y.; Yoshida, T.; Saijo, N.; Sawada, J.

Homozygous CDA*3 is a major cause of life-threatening toxicities in

gemcitabine-treated Japanese cancer patients. British Journal of Cancer 2009,

100, 870-873.

Umamaheswaran, G.; Krishna Kumar, D.; Kayathiri, D.; Rajan, S.; Shewade, D. G.;

Dkhar, S. A.; Manjunath, S.; Ushakiran, P.; Reneega, G.; Ritushree, K.;

Adithan, C. Inter and intra-ethnic differences in the distribution of the molecular

variants of TPMT, UGT1A1 and MDR1 genes in the South Indian Population.

Molecular Biology Reports 2012, 39, 6343-6351.

van Kuilenburg, A. B. Dihydropyrimidine dehydrogenase and the efficacy and

toxicity of 5-flurouracil. European Journal of Cancer 2004, 40, 939-950.

van Kuilenburg, A. B.; Baars, J. W.; Meinsma, R.; Gennip, A. H. Lethal 5-flurouracil

toxicity associated with a novel mutation in the dihydropyrimidine

dehydrogenase gene. Annals of Oncology 2003, 14, 341-342.

van Kuilenburg, A. B.; Haasjes, J.; Richel, D. J.; Zoetekouw, L.; van Lenthe, H.; De

Abreu, R. A.; Maring, J. G.; Vreken, P.; van Gennip, A. H. Clinical implications

of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe

5-fluorouracil-associated toxicity: identification of new mutations in the DPD

gene. Clinical Cancer Research 2000, 6, 4705– 4712.

van Kuilenburg, A. B.; Meijer, J.; Mul, A. N.; Meinsma, R.; Schmid, V.; Dobritzsch,

D.; Hennekam, R. C.; Mannens, M. M.; Kiechle, M.; Etienne-Grimaldi, M. C.;

Klumpen, H. J.; Maring, J. G.; Derleyn, V. A.; Maartense, E.; Milano, G.;

Vijzelaar, R.; Gross, E. Intragenic deletions and a deep intronic mutation

affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as

novel mechanisms causing 5-flurouracil toxicity. Human Genetics 2010, 128,

529-538.

van Kuilenburg, A. B.; Meinsma, J. R.; Zoetekouw, L.; van Gennip, A. H. Increased

risk of grade IV neutropenia after administration of 5-fluorouracil due to a

dihydropyrimidine dehydrogenase deficiency: high prevalence of the

IVS14+1G>a mutation. International Journal of Cancer 2002a, 101, 253–258.

van Kuilenburg, A. B.; Meinsma, J. R.; Poll-The, B. T.; Zoetekouw, L.; van Gennip,

A. H. Identification of a novel disease-causing mutation (100del A) in the

dihydropyrimidine dehydrogenase gene. International Archives of Bioscience

2002b, 1, 1096-1100.

van Kuilenburg, A. B.; Meinsma, R.; Zoetekouw, L.; Gennip, A. H. V. High

prevalence of the IVS14+1G>A mutation in the dihydropyrimidine

References

215


India, 2013

dehydrogenase gene of patients with severe 5-flurouracil-associated toxicity.

Pharmacogenetics 2002c, 12, 555-558.

van Kuilenburg, A. B.; Dobritzsch, D.; Meinsma, R.; Haasjes, J.; Waterham, H. R.;

Nowaczyk, M. J.; Maropoulos, G. D.; Hein, G.; Kalhoff, H.; Kirk, J. M.;

Baaske, H.; Aukett, A.; Duley, J. A.; Ward, K. P.; Lindgvist, Y.; van Gennip, A.

H. Novel disease- causing mutations in the dihydropyrimidine dehydrogenase

gene interpreted by analysis of the three-dimensional protein structure.

Biochemical Journal 2002d, 364, 157-163.

van Kuilenburg, A. B.; Muller, E. W.; Haasjes, J.; Meinsma, R.; Zoetekouw, L.;

Waterham, H. R.; Baas, F.; Richel, D. J.; van Gennip, A. H. Lethal outcome of a

patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency

after administration of 5-flurouracil: frequency of the common IVS14+1G>A

mutation causing DPD deficiency. Clinical Cancer Research 2001, 7, 1149-

1153.

van Kuilenburg, A. B.; Poorter, R. L.; Peters, G. J.; van Gennip, A. H.; van Lenthe,

H.; Stroomer, A. E.; Smid, K.; Noordhuis, P.; Bakker, P. J.; Veenhof, C. H. No

circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase,

beta- alanine, and 5-fluorouracil during continuous infusion of 5-fluorouracil.

Advances in Experimental Medicine and Biology 1998, 431, 811–816.

van Kuilenburg, A. B.; Vreken, P.; Abeling, N. G.; Bakker, H. D.; Meinsma, R.; van

Lenthe, H.; De Abreu, R. A.; Smeitnik, J. A.; Kayserili, H.; Apak, M. Y.;

Christensen, E.; Holopainen, I.; Pulkki, K.; Riva, D.; Botteon, G.; Holme, E.;

Tulinius, M.; Kleijer, W. J.; Beemer, F. A.; Duran, M. ; Niezen-Koning, K. E.;

Smit, G. P.; Jakobs, C.; Smit, L. M.; Van Gennip, A. H . Genotype and

phenotype in patients with dihydropyrimidine dehydrogenase deficiency.

Human Genetics 1999a, 104, 1-9.

van Kuilenburg, A. B.; van Lenthe, H.; Blom, M. J.; Mul, E. P. J.; van Gennip, A. H.

Profound variation in dihydropyrimidine dehydrogenase activity in human blood

cells: major implications for the detection of partly deficient patients. British

Journal of Cancer 1999b, 79, 620-626.

van Kuilenburg, A. B.; Vrecken, P.; Riva, D. Clinical and biochemical abnormalities

in a patient with Dihydropyrimidine dehydrogenase deficiency due to

homozygosity for the C29R mutation. Journal of Inherited Metabolic Disease

1999c, 22, 191-200.

Vicenzetti, S.; Cambi, A.; Neuhard, J.; Garattini, E.; Vita, A. Recombinant human

Cytidine deaminase: expression, purification and characterization. Protein

Expression and Purification 1996, 8, 247-253.

Victor, T. C.; Warren, R.; Butt, J. L.; Jordaan, A. M.; Felix, J. V.; Venter, A.; Sirgel,

F. A.; Schaaf, H. S.; Donald, P. R.; Richardson, M.; Cynamon, M. H.; van

Helden, P. D. Genome and MIC stability in Mycobacterium tuberculosis and

References

216


India, 2013

indications for continuation of use of isoniazid in multidrug-resistant

tuberculosis. Journal of Medical Microbiology 1997, 46, 847-857.

Vincenzetti, S.; Pucciarelli, S.; Carpi, F. M.; Micozzi, D.; Polzonetti, V.; Natalini, P.;

Santarelli, I.; Polidori, P.; Vita, A. Site directed mutagenesis as a tool to

understand the catalytic mechanism of human cytidine aminase. Protein and

Peptise Letters 2012 [Article in press].

Vogel, F. Moderne problem der humangenetik. Ergeb Inn Med U Kinderheilk 1959,

12, 52-125. (Scott, S. A. Personalized medicine with clinical

pharmacogenomics. Genetics in Medicine 2011, 13, 987-995).

Vogelstein, B.; Kinzler, K. W. Cancer genes and the pathways they control. Nature

Medicine 2004, 10, 789-799.

Vooberg, A, M.; van Beek, F. T.; Slee, P. H.; Seldenrijk, C. A.; Schramel, F. M.

Vasculitis due to gemcitabine. Lung Cancer 2002, 36(2), 203-205.

Vos, P.; Hogers, R.; Bleeker, M.; Reijans, M.; van de Lee, T.; Hornes, M.; Frijters,

A.; Pot, J.; Peleman, J.; Kuiper, M. AFLP: a new technique for DNA

fingerprinting. Nucleic Acids Research 1995, 23(21), 4401-4414.

Voutsadakis, I. A. Molecular predictions of gemcitabine response in pancreatic

cancer. World Journal of Gastroenterology Oncology 2011, 3, 153-164.

Vreken, P.; van Kuilenburg, A. B.; Meinsma, J. R.; Smit, G. P.; Bakker, H. D.; De

Abreu, R. A.; Van Gennip, A. H. A point mutation in the invariant splice donor

site leads to exon skipping in two unrelated Dutch patients with

dihydropyrimidine dehydrogenase deficiency. Journal of Inherited Metabolic

Disease 1996, 19, 645-654.

Vreken, P.; van Kuilenburg, A. B.; Meinsma, R.; Van Gennip, A. H.

Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and

expression of missense mutations C29R, R886H and R235W. Human Genetics

1997a, 101, 333-338.

Vreken, P.; van Kuilenburg, A. B.; Meinsma, R.; De Abreu, R. A.; Van Gennip, A. H.

Identification of a four-base deletion (delTCAT 296-299) in the

Dihydropyrimidine dehydrogenase gene with variable clinical expression.

Human Genetics 1997b, 100, 263-265.

Walko, C.M.; Lindley, C. Capecitabine: a review. Clinical Therapeutics 2005, 27(1),

23-44.

Wang, L.; Nguyen, T. V.; McLaughlin, R. W.; Sikkink, L. A.; Ramirez-Alvarado, M.;

Weinshilboum, R. M. Human thiopurine S-methyltransferase pharmacogenetics:

variant allozyme misfolding and aggresome formation. Proceedings of the

National Academy of Sciences of the United States of America 2005, 102, 9394-

9399.

References

217


India, 2013

Wang, Y.; Chen, J.; Zhang, Y.; Bin, L.; Sun, K.; Yu, W.; Liu, J.; Zhang, C.; Shen, H.;

Hou, Z.; Yu, F.; Hui, R. VKORC1 rs2359612C allele is associated with

increased risk of coronary artery disease in the presence of coronary

calcification. Human Genetics 2013, 132, 29-37.

Wang, Z.; Sew, P. H.; Ambrose, H.; Ryan, S.; Chong, S. S.; Lee, E. J.; Lee, C. G.

Nucleotide sequence analyses of the MRP1 gene in four populations suggest

negative selection on its coding region. BMC Genomics 2006, 7, 111.

Ward, J. L.; Sherali, A.; Mo, Z. P.; Tse, C. M. Kinetic and pharmacological properties

of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably

expressed in nucleoside transporter-deficient PK15 cells. Ent2 exhibits low

affinity for guanosine and cytidine but a high affinity for inosine. The Journal of

Biological Chemistry 2000, 275(12), 8375-8381.

Washington, C. B.; Giacomini, K. M.; Brett, C. M. Nucleoside transport in isolated

human and rhesus choroid plexus tissue slices. Pharmaceutical Research 1998,

15, 1145-1147.

Watanabe, S.; Uchida, T. Expression of Cytidine deaminase in human solid tumours

and its regulation by 1 alpha, 2,5- dihydroxyvitamin D3. Biochimica et

Biophysica Acta 1996, 1312, 99-104.

Waud, W. R.; Gilbert, K. S.; Shepherd, R. V.; Montgomery, J. A.; Secrist, J. A. III.

Preclinical antitumor activity of 4’-thio-beta-D-arabinofuranosylcytosine (4-

thio-ara-C). Cancer Chemotherapy and Pharmacology 2005, 51, 422-426.

Waxman, D. J. Glutathione S-transferases: role in alkylating agent resistance and

possible target for modulation chemotherapy- a review. Cancer Research 1990,

50, 6449-6454.

Weber, W. W. The acetylator genes and drug response. Oxford University Press, New

York, 1987.

Wei, X.; Elizondo, G.; Sapone, A.; McLeod, H. L.; Raunio, H.; Gonzalez, F. J.

Characterization of the human dihydropyrimidine dehydrogenase gene.

Genomics 1998, 51, 391-400.

Wei, X.; McLeod, H. L.; McMurrough, J.; Gonzalez, F. J. Molecular basis of the

human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.

The Journal of Clinical Investigation 1996, 98, 610–615.

Weiland, S.; Bertrand, D.; Leonard, S. Neuronal nicotinic acetylcholine receptors:

from the gene to the disease. Behavioural Brain Research 2000, 113, 43-56.

Weiland, S.; Witzemann, V.; Villarroel, A.; Propping, P.; Steinlein, O. An amino acid

exchange in the second transmemebrane segment of a neuronal nicotinic

receptor causes partial epilepsy by altering its desensitization kinetics. FEBS

Letters 1996, 398, 91-96.

References

218


India, 2013

Wilson, B.; Ambika, T. V.; Patel, R. D.; Jenita, J. L.; Priyadarshini, S. R.

Nanoparticles based on albumin: preparation, characterization and the use of 5-

flurouracil delivery. International Journal of Biological Macromolecules 2012,

51(5), 874-878.

Wong, A.; Soo, R. A.; Yong, W. P.; Innocenti, F. Clinical pharmacology and

pharmacogenetics of gemcitabine. Drug Metabolism Reviews 2009, 41, 77-88.

Woolhouse, N. M.; Qureshi, M. M.; Bastaki, S. M. A.; Patel, M.; Abdulrazzaq, Y.;

Bayoumi, A. L. Polymorphic N-acetyltransferase (NAT2) genotyping of

Emiratis. Pharmacogenetics 1997, 7, 73–82.

Xu, J.; Zhou, Y.; Zhang, J.; Chen, Y.; Zhuang, R.; Liu, T.; Cai, W. High incidence of

severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer

patients with 79A>C mutation. Clinica Chimica Acta 2012b, 413, 1284-1287.

Xu, P. P.; Chen, B. A.; Feng, J. F.; Cheng, L.; Xia, G. H.; Li, Y. F.; Qian, J.; Ding, J.

H.; Lu, Z. H.; Wang, X. M.; Xu, K.; Schultz, M. Association of polymorphisms

of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for

acute myeloid leukemia. Chinese Medical Journal 2012a, 125(12), 2137-2143.

Yamada, H.; Fukushima, M.; Koizumi, K.; Katakura, H.; Nakanishi, H.; Teshima, S.;

Kamiyama, Y.; Ikenaka, K. Regulation of dihydropyrimidine dehydrogenase

gene expression in regenerating mouse liver. International Journal of Oncology

2003, 22, 359–364.

Yang, J. J.; Zhou, Q.; Liao, R. Q.; Huang, Y. S.; Xu, C. R.; Wang, Z.; Wang, B. C.;

Chen, H. J.; Wu, Y. L. Nedaplatin/gemcitabine versus carboplatin/gemcitabine

in treatment of advanced non-small cell lung cancer: A randomized clinical

trial. Chinese Journal of Cancer Research 2012, 24(2), 97-102.

Yang, Q.; Du, J.; Yao, X. Significant association of glutathione s-transferase t1 null

genotype with prostrate cancer risk: a meta-analysis of 26,393 subjects. PLoS

One 2013, 8(1), e53700.

Yen, J. L.; Mcleod, H. L. Should DPD analysis be required prior to prescribing

fluropyrimidines? European Journal of Cancer 2007, 43, 1011-1016.

Yin, J. Y.; Huang, Q.; Yang, Y.; Zhang, J. T.; Zhong, M. Z.; Zhou, H. H.; Liu, Z. Q.

Characterization and analyses of multidrug resistance-associated protein 1

(MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenetics and

Genomics 2009, 19, 206-216.

Yokota H.; Fernandez-Salguero, P.; Furuya, H.; Lin, K.; McBride, O. W.; Podschun,

B.; Schnackerz, K. D.; Gonzalez, F. J. cDNA cloning and chromosome mapping

of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-

References

219

© Iyer Sandhya Natarajan & Institute of Chemical Technology (ICT) Mumbai, India, 2013

fluorouracil toxicity and congenital thymine uraciluria. The Journal of Biological Chemistry

1994, 269, 23192-23196.

Yonemori, K.; Ueno, H.; Okusaka, T.; Yamamoto, N.; Ikeda, M.; Saijo, N.; Yoshida, T.; Ishii,

H.; Furuse, J.; Sugiyama, E.; Kim, S. R.; Kikura-Hanajiri, R.; Hasegawa, R.; Saito, Y.;

Ozawa, S.; Kaniwa, N.; Sawada, J.; Severe drug toxicity associated with a single-

nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient

treated with gemcitabine plus cisplatin. Clinical Cancer Research 2005, 11, 2620-2624.

Yu, Y.; Weng, Y.; Guo, J.; Chen, G.; Yao, K. Association of glutathione S transferases

polymorphisms with glaucoma: A meta-analysis. PLoS One 2013, 8(1), e54037.

Yue, L.; Saikawa, Y.; Ota, K.; Tanaka, M.; Nishimura, R.; Uehara, T.; Maeba, H.; Ito, T.;

Sasaki, T.; Koizumi, S. A functional single-nucleotide polymorphism in the cytidine

deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 2003, 13, 29-38.

Zabost, A.; Roszkowska-`Siiz, B.; Waitr, E.; Radzikowska, E.; Rogala, E.; Zych, J.; Zwolska, Z.;

Augustynowicz-Kopec, E.; Roszkowski-`Siiz, K.; Szczepulska-Wojcik, E. Polymorphism

in the N-acetyltransferase 2 gene in patients with lung cancer. Pneumonologia I

Alergologia Polska 2012, 80(4), 323-328.

Zhang, J.; Liu, H.; Yan, H.; Huang, G.; Wang, B. Null genotypes of GSTM1 and GSTT1

contribute to increased risk of diabetes mellitus: A meta-analysis. Gene 2013 [Article in

press].

Zhou, L. P.; Yao, F.; Luan, H.; Wang, W. L.; Dong, X. H.; Zhou, W. W.; Wang, Q. H.

CYP3A4*1B polymorphism and cancer risk: A HuGE review and meta-analysis. Tumour

Biology 2012 [Article in press].

Zhu, J.; Chen, W.; Xu, S.; Wang, Y.; Sun, Z. GSTT1 null genotype is associated with an

increased risk of prostrate cancer in Caucasians: A meta-analysis. Urologia Internationalis

2013 [Article in press].

References - Shodhgangashodhganga.inflibnet.ac.in/bitstream/10603/25171/... · References © Iyer...

Documents

Transcript of References - Shodhgangashodhganga.inflibnet.ac.in/bitstream/10603/25171/... · References © Iyer...